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The inhibitor of DNA binding protein 4 (ID4) is a dominant negative regulator of 
basic helix loop helix (bHLH) family of transcription factors.1 Recently, Patel et al., 
demonstrated that inhibitor of differentiation 4 (ID4) acts as a tumor suppressor and its 
loss, frequently observed in prostate cancer, promotes castration-resistant prostate cancer 
(CRPC) through constitutive androgen receptor (AR) activation.2 However, the 
mechanism by which loss of ID4 promotes constitutively active AR signaling in the 
CRPC conditions is unknown. The rationale of the present study was to unravel the 
underlying molecular mechanisms through which loss of ID4 potentiates AR signaling in 
this setting. Initially, chromatin immunoprecipitation (ChIP) assay results demonstrated a 
significant increase in binding of AR to its respective response elements on PSA, 
FKBP51, TMPRSS2, and ETV1 promoters in L(-)ID4 cells, further implicating 
constitutive AR activity. Among the notable findings, proteomic profiling between 
                                                                       ii 
 
prostate cancer cell line LNCaP (L+ns) and LNCaP lacking ID4 (L(-)ID4) revealed 
elevated protein levels of Heat shock protein 27 (Hsp27) and the 52-kDa FK506-binding 
protein (FKBP52), suggesting a role for these AR-associated co-chaperones in promoting 
constitutively active AR signaling in L(-)ID4 cells. Interestingly, protein interaction 
studies further confirmed a direct interaction between ID4 and FKBP52 in vitro but not 
with AR. Recent evidences suggest that FKBP52 is a positive regulator of AR signaling 
in cellular and whole animal models.3-6 Thus, we hypothesized that ID4 acts as a tumor 
suppressor by selectively regulating AR activity through interaction with FKBP52. To 
address the underlying mechanism, we blocked the FKBP52-AR signaling using a 
specific inhibitory compound known as MJC13.4, 6-7 The results demonstrated that 
MJC13 effectively inhibited AR-dependent expression and activity in a dose-dependent 
manner. In addition, xenograft studies further confirmed that inhibiting FKBP52-
regulated AR activity via MJC13 significantly attenuated the growth of subcutaneous L(-
)ID4 xenografts in vivo. Collectively, our results suggested that ID4 selectively regulates 
AR activity through direct interaction with FKBP52 in vitro, and, its loss promotes CRPC 
through FKBP52-mediated AR signaling. Increased AR signaling along with a 
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The basic helix-loop-helix (bHLH) proteins belong to a large super-family of 
transcription factors that consist of more than 200 members across yeast and humans.8 
The bHLH proteins play an essential role in regulating the transcription of genes that are 
involved in cell fate determination.9-10 These proteins also regulate critical developmental 
processes such as differentiation in various cell types including B and T-lymphoctyes, 
muscle lineages, pancreatic B cells, neurons and osteoblasts.10-12 The four known 
inhibitors of DNA-binding (ID) proteins, ID1, ID2, ID3 and ID4 are largely considered as 
dominant negative regulators of bHLH family of transcription factors that lack the basic 
DNA-binding domain but have intact HLH domain.1 They can dimerize with bHLH 
proteins, but the heterodimer fails to bind DNA and activate E-Box dependent 
transcription of target genes.13-14 The interference of ID proteins with the key regulatory 
bHLH proteins is therefore an important interaction for proliferation and differentiation.15 
The ID proteins negatively regulate differentiation and promote proliferation; 
hence the expression of specific subsets of ID proteins is significantly increased in many 
different types of cancers.16 Whereas ID1, ID2 and ID3 are generally considered as tumor 
promoters, ID4 has now emerged as a potential tumor suppressor.15, 17-20 In most of the 





aggressiveness of the disease including poor prognosis, metastasis, and angiogenesis.21-25 
On the contrary, ID4 primarily acts as a tumor suppressor in most cancers as opposed to 
ID1, ID2 and ID3.26-28 Epigenetic silencing of ID4 in many cancers has prompted 
investigators to classify it as a tumor suppressor. Moreover, ID4 has been found to be 
epigenetically silenced in many different types of cancers including leukemia,29 AML,30-
34 CLL,35 ALL,36 glial neoplasia,37 squamous cell carcinoma,38 gastric cancer,39 
pancreatic cancer,40 prostate cancer,17, 20, 41 colorectal adenocarcinoma,42-43 malignant 
lymphoma,44 cholangiocarcinoma,45 esophageal,46 and lung47 cancers (Table 1). Overall, 
the epigenetic inactivation of ID4 due to promoter hyper-methylation appears to be the 
key mechanism in many cancers including prostate.19, 29, 48-50 
 
Table 1: Role of ID4 in Development and Different Cancers      
Development Cellular Expression Tumor Suppressor Tumor Promoter 
Proliferation  Adipocytes AML  Breast Cancer 
Differentiation Glial Cells CLL Glioblastoma 
Mammary 
Gland  
Neuronal Cells Colorectal Cancer Malignant Rhaboid 
Tumors 
Prostate Gland Prostate Epithelial 
Cells 
Cholongiocarcinoma Ovarian Cancer 
Spermatogenesis Spermatids Esophageal Cancer Breast Cancer 





Glial Neoplasia  
 Testicular Sertoli Cells Hodgkin’s Lymphoma  
  Leukemia  
  Lung Cancer  
  Pancreatic Cancer  
  Prostate Cancer  
  Squamous Cell 
Carcinoma 
 





Androgen signaling through androgen receptor plays an important role in the 
development and progression of prostate cancer.51-53 The androgen receptor not only 
mediates prostate development but also serves as a key regulator of primary prostatic 
cancer growth.54 The maturation of cytoplasmic androgen receptor to a mature hormone 
binding conformation is a highly ordered, dynamic process that involves multiple 
chaperone and co-chaperone components including Hsp90, FKBP51, FKBP52, P23, and 
PP5.6, 55 Recent evidences suggests that the 52 kDa FK506 binding protein (FKBP52) is 
an important positive regulator of AR in cellular and whole animal models and thereby 
represents an attractive therapeutic target for the treatment of prostate cancer.6 However, 
the potential mechanisms or regulatory events through which FKBP52 promotes AR 
signaling still remain largely unexplored. Given that AR signaling continues to play a 
critical role in the progression and development of castration-resistant prostate cancer 
(CRPC), blocking AR signaling through alternative mechanisms remains a relevant 
therapeutic strategy. 
While there are increasing evidences15, 17-18 to demonstrate that ID4 acts as a 
tumor suppressor in prostate cancer, and its loss, frequently observed in prostate cancer 
promotes a CRPC phenotype through constitutive AR activation,2 the molecular 
mechanism behind this transition remain unknown. In the present study, we hypothesized 
that “ID4 acts as a tumor suppressor by selectively regulating AR activity through 
interaction with FKBP52. Whereas, in the absence of ID4, FKBP52 stabilizes AR protein 





mediated transcriptional activity, ultimately leading to androgen-independent prostate 
cancer.” To investigate the given hypothesis, the following two aims were proposed:   
1. Investigate the cross-talk between ID4 and Androgen Receptor (AR) in normal   
prostate epithelial and prostate cancer cells. 







2.1 Prostate Gland 
The prostate gland is a male sex accessory gland and is an important part of the 
male reproductive system.56-57 It is an organ that surrounds the urethra of males at the 
base of the bladder, comprising of a muscular portion, which controls the release of urine, 
and a glandular portion, which secretes an alkaline fluid that constitutes a small volume 
of the semen.57-58 In general, a healthy human prostate is a walnut-sized gland located 
between the urinary bladder and penis (Figure 1A). The mean weight of the normal 
prostate in adult males is about 11 grams. Its main function is to produce the fluid portion 
of semen that supports, nourishes, and also facilitates sperm motility.57 The normal adult 
prostate is composed of a glandular epithelial and a fibromuscular stromal compartment. 
The epithelium is composed of two major histologically distinct layers: secretory luminal 
and basal cell layer.57, 59 The secretory luminal layer is made up of tall columnar cells that 
are responsible for the production of PSA, PAP, and hK2 mainly secreted as part of the 
seminal fluid. The basal layer is believed to be the proliferative compartment of the 
prostate.57, 60-61 In comparison, a fibromuscular stromal compartment mostly consisting of 
extracellular matrix, stromal growth factors, and androgens are essential for functional 
and morphological differentiation of prostatic epithelium.57, 62 There are four major zones 





zone, and the anterior fibromuscular stroma (Figure 1B). All of these prostate zones 
differ in terms of their histology and biology.58, 61, 63 The peripheral zone is the largest 
zone of the prostate gland, which is located on the posterior side of the prostate. The 
peripheral zone is the site of origin of most carcinomas (approximately 75%) and 
prostatic intraepithelial neoplasia (PIN).57-58 The paired central zone is posterior to the 
stromal region and is resistant to carcinoma and other disease.64-65 Interior to the central 
zone is the transition zone, which is located on either side of the urethra between the 
peripheral and central zones. The transition zone is the smallest zone and constitutes 
about 20% of the prostate gland until the age of 40.65 As men ages, the transition zone 
begins to enlarge, until it becomes the largest area of the prostate. This phenomenon is 
known as benign prostatic hyperplasia (BPH).56, 58, 61, 63 The significance of this 
architecture is based upon the relationship of these zones to prostatic disease (Figure 1C). 
A                                                                           B                                                                                  









                                      
Figure 1. Adult prostate, zones and stages of prostate cancer. (A) A general overview of the prostate gland. 
(B) Anatomy of the prostate gland. The three histologically distinct zones are shown: the central zone, the 
transitional zone, and the peripheral zone. (C) A schematic view of the different stages of prostate cancer. 
 
2.2 Androgen Receptor 
The androgen receptor (AR) is a ligand activated transcription factor and 
important member of the steroid hormone receptor (SHR) that belongs to the subfamily 
of nuclear receptors.66 AR is a 919 amino-acid protein encoded from a ~180 kb gene that 
is located at chromosome Xq11-12.
66-67 Structurally, AR is comprised of four major 
functional domains: N-terminal domain, DNA-binding domain, androgen-binding 
domain, and the important hinge region (Figure 2). The androgen receptor mainly 
functions as a steroid-hormone activated transcription factor. In the absence of ligand, 
AR is primarily sequestered in the cytoplasm by heat-shock proteins, which masks its 
nuclear localization sequence (NLS).68-69  
Upon androgen stimulation, these chaperone proteins dissociate and the AR 
dimerizes, resulting in a conformational change which exposes the NLS. This results in 





androgen response elements (AREs) on regulatory regions of target genes and activate 
androgen-responsive genes.70  
                   
Figure 2. Protein structure of the human androgen receptor. The AR is composed of four different 
structural domains: the N-terminal domain (NTD) containing the activation function 1 (AF1) domain, the 
DNA binding domain (DBD), the ligand binding domain (LBD) containing the activation function 2 (AF2) 
domain and the hinge region where the KLKK motif resides. 
 
2.3 AR in the Normal Prostate 
The androgen receptor (AR) is an important member of the nuclear hormone 
receptor subfamily of transcription factors, necessary for the normal growth, terminal 
differentiation, and function of male urogenital structures, including the prostate gland.71 
Androgens acting through the androgen receptor are required for normal prostate 
development and prostate function by regulating transcription, cellular proliferation, and 
apoptosis.72-73 The prenatal development of the prostate is dependent on androgen action 
through an axis involving the testicular synthesis of testosterone, transport to target 
tissues, and the conversion to a more active metabolite 5α-dihydrotestosterone (DHT) by 
enzyme 5α-reductase.74-75 Testosterone and DHT exert their biological effects through 





The androgen-induced transcriptional activation of AR is modulated by a series of 
interactions of AR with multiple chaperones, co-chaperones, co-regulators, and also via 
phosphorylation of AR and AR-specific co-regulators in response to different growth 
factors.73, 76 The initiation of prostate development is mostly dependent on a functional 
AR. Generally, normal prostate epithelium expresses AR in late fetal or early neonatal 
development when AR function has been implicated in the final morphogenesis of the 
prostate and the initiation of prostate secretory protein expression. In addition, several 
research studies have also shown that prostate is completely absent in AR knockout 
mice,77 testicular feminized (Tfm) mice, and also in individuals with complete androgen 
insensitivity syndrome due to an inactivating mutation of AR.75, 78-79
 
Figure 3. Androgen-AR action in the prostate. Testosterone (T) and DHT bind to AR and promote the 
association of AR coregulators (ARAs). AR then translocates to the nucleus and binds to AREs in the 






2.4 Prostate Cancer Incidence, Progression and Therapeutics 
The prostate is an androgen-dependent organ and prostate cancer is an androgen-
dependent disease.80 Prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for 
men.80 It is also the leading cause of morbidity and mortality in the United States and 
worldwide among men of all races. In 2013, in the United States alone, the American 
Cancer Society had estimated that more than 238,590 new cases of prostate cancer were 
diagnosed, while more than 29,720 men died of the disease.81 In 2014, it is estimated that 
233,000 new cases were diagnosed with 29,480 estimated deaths.82 It is most common in 
black men, followed by Caucasians, and least common in Asians.80 The incidence rate of 
prostate cancer dramatically increases in later stages of life and affects men at a ratio of 
1:9 over the age of 65.83-84 By age 90, it is estimated that 90% of men will have PCa. In 
addition, more than 65% of all PCa will be diagnosed in men 65 years of age or older, 
and 9% of patients will be 70 years of age or older.85 A better understanding of prostate 
cancer risk factors can lead to better identification and treatment of prostate cancer. The 
well-established risk factors which may increase the likelihood of a person to develop 
prostate cancer mainly include age, race, family history, and environmental factors 
including diet, life styles, and exposure to chemical agents.86 Over 95% of all the prostate 
cancers arise from differentiated prostatic epithelial and/or progenitor cells in which the 
embryonic pathways are reactivated through the activation of oncogenes and subsequent 
loss of tumor suppressor genes, further leading to increased tumor growth and survival 





with a dysplasia that initiates with proliferative inflammatory atrophy (PIA) and 
ultimately progresses to prostatic intraepithelial neoplasia (PIN), which in some cases 
may even lead to prostate carcinoma.87-88 Androgen signaling through androgen receptor 
is critical for prostate cancer progression and development.51 The clinical success rates of 
different therapeutic approaches that directly target androgen receptor, androgen 
synthesis as well as the common abnormalities of the AR confirm that prostate cancer 
remains dependent on AR signaling, even in the castrate state.89-90 Given the critical role 
of AR in prostate cancer progression and development, there is a need for the 
identification, characterization, and therapeutic targeting of novel molecular mechanisms 
and regulatory proteins involved in aberrant AR activation in prostate cancer.  
 
2.5 Molecular Mechanisms of Prostate Cancer Initiation and Progression  
In the normal prostate, the balance between low rates of proliferation and low 
levels of apoptosis maintain homeostasis. In case of prostate cancer, there is a disturbance 
of this balanced state.91 Luminal cells are the proposed cells of prostate cancer origin 
primarily due to the presence of luminal cell markers in prostate cancer cells.92 Emerging 
evidences suggests that prostate carcinoma cells in fact carry specific markers, both of 
basal cells as well as those of secretory luminal cells.59 The most abundant population of 
secretory luminal cells, mostly expresses cytokeratin 8 (CK8), cytokeratin 18 (CK18), 
prostate specific antigen (PSA), high level of androgen receptor (AR) and are dependent 
on androgen for survival.93 Whereas basal cells, the second most common cellular 





cytokeratin 5 (CK5), cytokeratin 14 (CK14), and low levels of AR.93-95 Histopathological 
studies of prostate cancer tissue have concluded that prostatic intraepithelial neoplasia 
(PIN) is a precursor of prostate carcinoma.87 Initially, PIN lesions are primarily found in 
the peripheral zone, in a closer proximity to invasive carcinoma.87 PIN eventually leads 
to invasive carcinoma, characterized by loss of basal lamina, over proliferation of basal 
and luminal cells, and full expression of markers associated with invasive carcinoma such 
as matrix metalloproteinase-2 (MMP2).96 In general, development of any cancer reflects 
a progressive and cumulative alteration in various genes. Over the past few years, 
significant efforts have been made in understanding the molecular basis of prostate 
cancer. A number of mouse models including Pten-/-, Myc hi/lo, Nkx3.1-/-, Id4-/-, and 
several others have been developed in order to recapitulate the several aspects of PCa 
initiation and progression.97-101 Furthermore, several oncogenes, tumor suppressor genes, 
DNA repair genes, and metastasis suppressor genes have been extensively investigated in 
prostate cancer.60 Among the established tumor suppressor genes, losses of p53 and 
PTEN are primarily involved in the progression of prostate carcinoma. In addition, losses 
of chromosome 16q, 17p and 10q, depending on their location, occur with moderate 
frequencies in advanced cancers.102 Together, based on the cumulative research findings, 
few of the important factors that have been known to be potentially involved in the 
development and progression of prostate cancer include altered E-cadherin expression, 
inactivation of GSTP1 (11q13), loss of NKX3.1 (8p21), RB1(13q) and KAI-1 (11p), 
overexpression of EZH2 polycomb protein, transcriptional silencing of many genes by 





availability of adrenal steroids, AR gene amplification, mutation, and post-translational 
modifications of AR protein including its abnormal phosphorylation by a distinct set of 
co-regulators.59-60, 87, 92 Studies in both humans and animal models suggest a relationship 
between the cellular AR level in both primary and metastatic lesions and subsequent 
disease progression.51  
 
2.6 AR Expression during Prostate Carcinogenesis 
The primary role of androgen receptor (AR) signaling axis in the development 
and progression of prostate cancer has led to increasing interest in this particular nuclear 
receptor.51, 103 AR activity through androgens is intimately linked to prostate cancer, 
which is by far the most commonly diagnosed cancer among American men and the 
second leading cause of cancer deaths.104-105 AR expression is observed in primary 
prostate tumors and can also be detected throughout progression in both hormone-
sensitive and hormone-refractory cancers.106-108 In addition, prostate-specific antigen 
(PSA), which is encoded by an androgen-responsive gene, has been detected in the 
majority of hormone-refractory cancers, indicating that the AR-signaling pathway is still 
functional in these cancers.109 Immuno-histochemical studies have shown that AR 
expression is heterogeneous in prostate cancer and the degree of heterogeneity does not 
correlate with response to androgen deprivation therapy.106, 108 In the recent years, 
different mechanisms that have been identified through which AR promotes prostate 
tumorigenesis include AR hypersensitivity, constitutive AR activation via cross talk with 





altered recruitment, and expression of AR-specific co-regulators.110 The primary role of 
AR in prostate cancer is to regulate expression of the genes that are essential for prostate 
cancer cell growth and tumorigenesis.111 AR-mediated transcriptional regulation is often 
deregulated through multiple mechanisms involving mutations in the AR gene, increased 
expression of AR protein, growth factor-induced activation of AR, and aberrant 
functioning of AR-interacting protein partners.112 AR co-activators are known to enhance 
AR activity and PCa cell survival through multiple post-translational modifications 
including phosphorylation, acetylation, methylation, ubiquitination, sumoylation, and 
stabilization of AR protein levels via interaction with multiple chaperones and co-
chaperones.72, 112 These chaperones (and/or co-chaperones) include Hsp90, FKBP51, 
FKBP52, CYP40, and PP5.113-114 In addition, the transactivation of AR is often regulated 
by a number of different co-regulators including SRC-1, p300, TIP60, DJ-1, β-
CATENIN, GSK-3β, TCF4, and many others, further indicating that altered expression of 
different co-regulators might be potentially involved in promoting prostate 
tumorigenesis.112 However, very little is known about the expression of co-regulators or 
the crosstalk of the other signaling pathways with AR in Pca.51 All of these mechanisms 
clearly suggest that PCa and CRPC remain largely dependent on the AR signaling for 
growth and survival. Thus, targeting AR signaling is considered one of the most 






2.7 Modulation of AR Transcriptional Activity in Prostate Cancer               
Functional studies have shown that the AR pathway is essential for cell viability, cellular 
proliferation, differentiation, and invasion in both hormone-sensitive and hormone-
refractory prostate cancers.2, 115-116 As a transcription factor, the oncogenic functions of 
AR are mainly mediated through regulation of specific target genes that are known to be 
primarily involved in PCa cell growth, progression, and development.117 For example, 
important AR-regulated target genes known to be involved in promoting prostate 
tumorigenesis include PSA, FKBP51, TMPRSS2, ETV1, E2A, NDRG1, ARD1 and 
many more.6, 117-118 Among the most notable ones, critical factors that have been 
identified to contribute to the initiation and maintenance of aberrant AR-regulated 
signaling in castrate-resistant disease mainly include activating mutations, gene 
amplifications, altered activity and overexpression of specific co-regulators and to some 
extent, even growth factor mediated modulation of AR activity as detailed below.73, 119 
 
2.7.1 Genetic Alterations in AR  
Genomic alterations with a potential involvement in prostate cancer include 
somatic mutations, gene deletions, amplification, and chromosomal rearrangements.120 
Given the heterogeneous nature of AR expression in prostate cancer due to its genetic 
instability, androgen signaling through AR might serve as an important prerequisite event 
for disease aggressiveness.119, 121 Also, the structural and functional abnormalities of AR 
appear to confer the resistance of tumor cells to hormonal ablation and facilitate their 





alterations in the AR structure, expression, and signaling could play a determining role in 
the progression of prostate cancer toward an incurable androgen-independent (AI) 
state.120-122 In addition to cytoplasmic signaling crosstalk, somatic mutations, germline 
mutations, cross-modulation by multiple nuclear transcription factors, crosstalk with 
other kinases, AI progression of prostate cancer may also result from genetic changes in 
the AR.121 Considering the nature of genetic changes, important mechanisms that may 
contribute to the genetic alterations of the AR for metastatic or AI progression of prostate 
cancer include genomic amplification of AR, hypersensitive AR resulting from point 
mutations, promiscuous mutant AR protein activated by non-androgenic ligands and to 
some extent, even AR-polymorphisms, further modulating the sensitivity of AR response 
to androgens.73, 121 
 
2.7.1.1 AR Mutations  
Abnormal functioning of the AR pathway mainly due to genetic changes in the 
androgen receptor leads to the development of castration-resistance, further allowing the 
tumor cells to avoid the normal stimuli to growth.120 In untreated prostate cancer, the 
presence of AR mutations is directly proportional with the increasing cancer stage.73 AR 
mutations are usually found in 0-4% of latent and stage B prostate tumors.123-124 
However, AR mutations increase to 21-44% in metastatic tumors sampled before 
therapy.123, 125 The increased frequency of AR mutations in tumors before hormonal 
therapy suggests that hormonal therapy itself does not drive mutagenesis of AR, although 





The majority of the AR mutations identified from prostate carcinoma samples are point 
mutations resulting in a single amino acid substitution. These mutations are 
predominantly localized to the AR-ligand binding domain.126-127 Important somatic 
mutations in the AR gene, resulting in an increase of the potential ligands which bind and 
activate the androgen receptor include missense mutations like T877A and L701H.120 The 
most frequently occurring mutation of this type is the AR T876A mutation, which has 
been reported to occur in 25% (6 of 24 patients)128 and 31% (5 of 16 patients)129 of 
hormone refractory metastases after combined androgen blockade. Moreover, the AR 
T876A mutation allows the anti-androgens to activate AR transcription and stimulate the 
proliferation of LNCaP cells.130-131 In addition to antiandrogens, the AR T876A mutant 
can be activated by DHEA,132-133 androstenediol,134 estradiol, and progesterone.130-132, 135 
Given that most of the AR mutations are associated with an increased transcriptional 
response to DHEA,133 it is possible that increased AR transcriptional activity by adrenal 
androgens in addition to testicular androgens contributes to increased prostate cancer risk 
in these individuals.73   
 
2.7.1.2 AR Amplification  
Several mechanisms have been implicated in aberrant AR reactivation in the 
castration resistant environment. These include AR mutations, AR amplification and 
local androgen synthesis.136 The amplification of the AR gene has been suggested as a 
key mechanism that enables prostate cancer cells to become sensitive even to the reduced 





rarely occur in untreated primary prostate cancers, with an observed frequency between 0 
and 5%.137-140 However, amplification of AR is found in 20-30% of hormone refractory 
prostate cancers.138-142 In addition, several studies have confirmed that the association 
between AR amplification and hormone refractory prostate cancer is mainly due to an 
increase in the AR gene copy number under conditions of androgen deprivation. This is 
because an elevated levels of AR gene expression could equally contribute to the ability 
of cancer cells to proliferate in a reduced androgen environment.73 However, it still 
remains unclear whether amplification of the AR gene in hormone refractory tumors 
results in an increase in AR protein levels. In other words, the significance of AR 
amplification in prostate cancer still remains unknown. 
 
2.7.2 AR Co-Regulator Overexpression  
A cascade of ligand-loaded and AR initiated protein-protein interactions can 
cause the stepwise remodeling of chromatin structure at target promoters, recruitment of 
basal transcription machinery and initiation of RNA polymerase activities. All these 
events can be modulated by a subset of more than 130 putative AR interacting co-
regulators that can either promote (coactivators) or inhibit (corepressors) AR function.71, 
73 Moreover, aberrant activity, mutations or overexpression of these specific co-regulators 
can largely define the transcriptional activity of AR.73 A number of molecular studies 
have demonstrated that the physical interactions between AR and associated co-
regulators can influence the natural history of prostate cancer including deregulated 





regulators can be broadly classified into 4 major categories: (i) molecular chaperones and 
co-chaperones including HSP40, HSP70, Hsp90, FKBP51, FKBP52, CYP40, PP5 and 
many others that can coordinate maturation and movement of AR protein structure, (ii) 
histone modifiers such as CBP/p300, pCAF, NCoR, CARM1 and PRMT1, (iii) 
coordinators of transcription such as TRAP/DRIP/ARD and (iv) DNA structural 
modifiers such as SWI/SNF/BRG1.6, 71, 112 In recent years, FKBP51,143 FKBP52,4, 6 
CYP40,143 p300,144 NCoR,145-146 CARM1,147 PRMT1,148 and TRAP149 have been 
extensively studied and characterized among the most consistently overexpressed genes 
in prostate cancer.  
 
2.7.3 Growth Factor Modulation of AR Activity 
Prostate cancer progression is often associated with alteration of growth factor or 
growth factor receptor expression by the tumor. Unlike steroid hormones, growth factors 
and cytokines regulate multiple cellular responses through binding to membrane 
receptors. In the prostate, AR is among the important transcription factors whose activity 
is influenced by an increasing number of signal transduction cascades either through 
direct phosphorylation of AR or though phosphorylation of AR specific co-regulators. 
Growth factor modulation can result in either stimulation or inhibition of AR 
transcriptional activity.73 Moreover, a growth factor response that enhances AR activity 
in majority of prostate cancers may also be able to promote AR-mediated cell 
proliferation at the castrated levels of androgens.73 Important growth factors and 





include epidermal growth factor (EGF), insulin-like growth factor 1 (IGF1), keratinocyte 
growth factor (KGF), transforming growth factor beta (TGFβ), interlukin 6 (IL-6), 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κβ) and proline-rich 
tyrosine kinase 2 (PYK2).73 
 
2.8 Castration-Resistant Prostate Cancer 
Castration-resistant prostate cancer commonly known as CRPC is a clinical 
condition in which patients can no longer respond to medical or surgical castration. In 
other words, CRPC is the emergence of prostate cancer cells that have adapted to the 
hormone-depleted environment of the prostate.85, 150 CRPC is usually detected in patients 
with elevated PSA levels, with new symptoms on androgen deprivation therapy (ADT) or 
with new evidence of disease on bone scans or computed tomography scans.151 Previous 
studies have demonstrated that CRPC is stimulated by androgens and remains largely 
dependent on androgen receptor (AR) signaling. In majority of the CRPC cases, AR 
mRNA and protein expression levels have been found to be several-folds higher as 
compared to the primary untreated prostate tumors.102, 150, 152 In early to late stages of the 
castration-resistant disease, wherein tumors are less sensitive to androgen depletion, few 
of the important mechanisms that have been known to promote AR signaling includes 
changes in AR expression, gene amplification, activating mutations, alternative splicing, 
post-translational modifications (PTMs), and signaling cross-talk with several other 
oncogenic pathways.80, 152 CRPC cells are known to consistently overexpress major AR-





castration-resistant mechanism in AR-positive CRPC cells.150 Studies using multiple 
prostate cancer cell lines and in vivo xenograft models have also demonstrated that 
progression to CRPC is associated with elevated levels of AR and AR-dependent gene 
expression. In addition, blocking AR signaling in these cell lines by specifically targeting 
AR co-regulatory proteins can significantly suppress tumor growth, further implicating 
the therapeutic importance of AR signaling in the androgen depleted environment.152 
Since the clinically available therapeutic options including androgen deprivation, classic 
AR antagonists, and inhibitors of de novo steroidogenesis ultimately fail,153 in order to 
resolve the clinical problem of CRPC, it is important to understand the molecular basis 
for AR reactivation and its aberrant signaling in CRPC.153 
 
2.9 FKBP52 
FKBP52 is a 52-kilodalton (kDa) protein that belongs to a subclass of 
immunophilin protein family known as FK506-binding proteins (FKBPs), based on its 
ability to bind the immunosuppressive drug FK506.154 The FK506-binding site of 
FKBP52 contains peptidyl-prolyl cis-trans isomerase (PPIase) activity. PPIase (also 
known as rotamase activity) is a chaperoning function that catalyzes the conversion of 
prolyl-peptide bonds from trans- to cis-proline, which is often considered as a rate-
limiting step in protein folding.5, 154 Studies have previously shown that the FKBP52 is 
composed of four distinct domains (Figure 4). The first two domains include a functional 
site for PPIase activity and PPIase-like region. The first 138 amino acids from the N-





catalytic activity on the respective peptide substrates. A noteworthy aspect of the second 
domain, other than the close relation to a PPIase activity site of FK1 domain, is a 
consensus ATP/GTP-binding sequence between amino acids 199 and 222.154 Three 
tetratricopeptide repeat (TPR) domains occupy the third structural domain, while the 
fourth C-terminal domain contains a putative binding site for calmodulin.154             
                                                                                    
Figure 4. Functional domains of human FKBP52. (A) PPIase, peptidyl-prolyl cis-trans isomerase activity 
site. (B) TPR, tetratricopeptide repeat domains responsible for interaction with Hsp90. 
 
2.9.1 Biological Functions of FKBP52 
FKBP52 plays a pivotal role in the immuno-regulation and basic cellular 
processes involving protein folding and trafficking of many steroid receptors.114, 154-155 In 
addition, FKBP52 plays an essential role in the growth and development of the male 
genitalia.113, 155 Previous studies have demonstrated that FKBP52 is an important 
component of androgen receptor (AR) and other proteins in a complex with heat shock 
protein 90 (Hsp90). However, FKBP52 can only stably bind a client protein if Hsp90 is 
present.154 In 2003, Riggs et al., have shown a potentiation of GR-mediated reporter gene 
expression by expressing human FKBP52 in S.cerevisiae, which does not express a 





binding and subsequent transcriptional activity was seen with FKBP51, PPR5 or over-
expressed Cpr7 (yeast homolog of Cyp40).156 These findings strongly implicate that 
FKBP52 may itself be capable of maintaining glucocorticoid receptor (GR) in a high 
affinity state for hormone binding.154 However, the molecular mechanisms involved in 
the signaling and subcellular trafficking of receptors via FKBP52 still remains elusive.  
 
2.9.2 Role for Co-Chaperone FKBP52 in AR Signaling 
The maturation of cytoplasmic steroid hormone receptor such as androgen 
receptor (AR) to a mature hormone binding conformation is a highly ordered, dynamic 
process that involves the molecular chaperone such as Hsp90 as well as multiple co-
chaperones and different tetratricopeptide repeat (TPR) proteins. These co-chaperones 
include FKBP51 and FKBP52 (FK506-binding protein 51 and 52, respectively), CYP40, 
(cyclophilin 40) and PP5 (protein phosphatase 5).113-114 Each TPR protein enters into 
steroid receptor complexes through a direct and competitive binding at the C terminus of 
Hsp90 (MEEVD motif) via its essential TPR domain. Although FKBP51 and FKBP52 
share a similar domain structure, 60% sequence identity, and 75% similarity, FKBP51 is 
missing a C-terminal calmodulin-binding domain.113 As compared to FKBP51, FKBP52 
is required for normal male sexual differentiation and development in mice as the 
fkbp52-deficient mice displayed characteristics of partial androgen insensitivity 
syndrome including dysgenic prostate.113-114, 155 Moreover, the molecular studies in 
mouse embryonic fibroblast cells from fkbp52-/- mice uncovered that FKBP52 is critical 





domain of FKBP52 and in particular the proline rich loop of FKBP52 that overhangs its 
PPIase catalytic pocket, is critically involved in promoting androgen receptor interactions 
and activity.157 Moreover, recent evidences also implicates that AR transcriptional 
enhancement does not require FKBP52 mediated PPIase catalytic activity. However, the 
FKBP52 proline-rich loop that over-hangs the PPIase pocket is critical for AR signaling.5 
In other words, FKBP52 is a critical AR folding factor and also an important positive 
regulator of AR in cellular and whole animal models and represents an attractive target 
for the treatment of prostate cancer.6, 154  
 
2.10 ID Proteins 
The members of the basic helix-loop-helix (bHLH) family of transcription factors 
play an important role in regulating tissue-specific transcription.8, 10 Members of this 
protein family have two highly conserved domains. The carboxyl terminal contains the 
helix loop helix (HLH) domain involved in forming a homo or hetero-dimer with other 
bHLH proteins whereas the N-terminal consists of the basic DNA binding domain that 
binds to DNA sequences called E-box.13 They play a pivotal role in different 
physiological processes including cellular differentiation, apoptosis, cell cycle arrest, and 
several other important developmental processes.158 The inhibitor of DNA-binding (ID) 
proteins, ID1-4 are dominant negative regulators of basic helix-loop-helix (bHLH) family 
of transcription factors that lack the basic DNA-binding domain, as a result of which the 
ID proteins can dimerize with other bHLH proteins but the heterodimer fails to bind 





proteins regulate the function of various ubiquitously expressed and tissue specific bHLH 
transcription factors as well as non-bHLH proteins with different affinities.159 ID proteins 
play a critical role in coordinated regulation of cell growth, differentiation, tumorigenesis 
and angiogenesis.160 In general, the expression of ID proteins (ID1-ID3) is high in 
proliferating cells as they promote cell proliferation,161-162 and then expression is down 
regulated during differentiation.9 The expression of ID1, ID2, and ID3 proteins is 
increasingly observed in many cancers and in most cases associated with aggressiveness 
of the disease including poor prognosis,22-23, 163-164 metastasis,24 and angiogenesis.25, 165 In 
comparison to other IDs, ID4 has emerged as a tumor suppressor in most cancers and is 
an important part of cancer associated epigenetic re-programming.17 
                               A.                                       B. 
                                     
Figure 5. Structural features of bHLH and ID proteins. (A) Basic helix-loop-helix (bHLH) transcription 











ID4 is located on a 4 Mb region on chromosome 6p22.3 and consists of three 
exons.166 Exons 1 and 2 code for the ID4 protein whereas exon 3 serves as a 3̍ un-
translated region. ID4 is the longest protein within the ID protein family with a total of 
161 residues and also shares the core HLH domain. However, the N- and C-terminal 
domains of ID4 are highly divergent as compared with other ID proteins.167 The subtle 
changes in the core HLH domain but highly divergent N-terminal (alanine rich) and C-
terminal (proline rich) domains might play a pivotal role in assuming the unique 
functional properties of ID4 as opposed to the other ID protein family members.159 The 
poly-alanine rich N-terminal tract in ID4 first appeared in primitive mammals such as 
opossum but was found to be absent in lower vertebrates such as alligators, xenopus, 
zebra fish, and birds.159 Moreover, structural studies suggest that none of the N- and C-
terminal fragments of any of the ID proteins adopts a helical confirmation, except the N-
terminal 27-64 fragment of ID4, a motif that is characterized by the alanine residues 39-
48.168 Thus, the poly-alanine rich N-terminal tract could be a functionally important 
domain in ID4.159 The relatively low complexity in proline rich region in ID4 strongly 
implicates that ID4 lacks a well-defined 3-D structure at the C-terminal domain which in 
turn facilitates multiple protein-protein interactions by presenting a larger interaction 
surface, thereby allowing binding of multiple protein partners.169-170 Overall, structural 
modifications in ID4 through acquisition of unique functionally relevant domains suggest 
its potential involvement in development and differentiation as compared to ID1, ID2, 





2.11.1 ID4 in Development 
ID proteins are expressed by all cell lineages at some point during embryonic 
development.9 Unlike other ID proteins, ID4 is highly expressed during premature 
differentiation of early cortical stem cells.171-173 Accumulating evidences also suggests 
that ID4 expression is relatively high in undifferentiated, proliferating populations and is 
subsequently down-regulated as these cells begin to exit from cell cycle and get 
terminally differentiated.9 In adult human tissues, ID4 expression is observed in the brain, 
thyroid, testis, and pancreas.174 Moreover, ID4 is highly expressed in osteoblasts,175 
adipocytes,176 prostate epithelial cells,98 neurons,177 testicular sertoli cells,172 and also in 
glial cells during differentiation,178 further supporting its role as a pro-differentiation 
factor. ID4 plays an essential role in the development of different organs including neural 
compartments,173, 177 normal mammary,179 and prostate gland.98 In oligodendrocyte 
progenitor cells (OPCs), overexpression of ID4 inhibits differentiation along with a 
subsequent decrease in the endogenous expression of all myelin genes.180 Moreover, 
OPC’s lacking ID4 display early differentiation and increased apoptosis, further 
implicating the critical role of ID4 in the development of oligodendrocytes.180 In addition, 
ICC studies have shown that ID4 is localized to the nucleus in OPC’s181 and spermatids, 
but remains cytoplasmic in spermatocytes.182 The integration of various cellular events 
including response to specific ligands and cell specific protein-protein interactions could 
also possibly determine whether ID4 regulates proliferations and/or differentiation and 
cellular localization. Collectively, these studies suggest that ID4 can act as pro- or anti-





2.11.2 ID4 in Cancer: Tumor Promoter vs Tumor Suppressor 
In comparison to other ID proteins, the function of ID4 is less understood and 
often conflicting. The specific nature of ID4 protein expression in cancer has not been 
clarified, however studies support that ID4 has both pro-tumor and anti-tumor activity.159 
ID4 appears to act primarily as a tumor suppressor in most cancers as opposed to ID1, 
ID2, and ID3 which acts as tumor promoters or supporting oncogenes.26-28 Epigenetic 
silencing of ID4 in leukemia,29 AML,30-34 CLL,35 ALL,36 glial neoplasia,37 squamous cell 
carcinoma,38 gastric cancer,39 pancreatic cancer,40 prostate cancer, 17, 20, 41 colorectal 
adenocarcinoma,42-43 malignant lymphoma,44 cholangiocarcinoma,45 esophageal,46 and 
lung47 cancers tend to support its anti-tumor activity (Figure 6). In a small subset of 
cancers, ID4 also acts as a tumor promoter.183-190 For instance, high ID4 expression in a 
B-cell acute lymphoblastic leukemia183 and B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL)184 due to (6;14)(p22;q32) chromosomal translocation, breast,191-193 
bladder,185 and in rat mammary gland carcinomas186 suggests that it may have pro-tumor 
activity as well (Figure 6). Overall, recent studies have concluded that ID4 is highly 
expressed in the normal prostate and decreased in prostate cancer primarily due to 





       
Figure 6. Expression profile of ID4 in different cancers. (A) ID4 expression profile in various cancers from 
the Oncomine database. The blue and red boxes represent cancers in which ID4 expression is increased or 
decreased respectively as compared to normal counterparts. (B) The ID4 expression in various cancers 
from literature mining. The green line points to cancers in which ID4 is down-regulated whereas red lines 
points to cancers where ID4 is up-regulated. 
 
2.11.3 ID4 as a Tumor Suppressor in Prostate Cancer 
ID4 is required for normal prostate morphogenesis wherein, it is specifically 
expressed in the luminal epithelial cells. Interestingly, ID4-/- mice models exhibit 
relatively smaller sized prostates, decreased branching morphogenesis and often display 
peculiar characteristics of prostatic intra-epithelial neoplastic (PIN) lesions, the earliest 
precursor of prostate cancer.98, 159  Previous studies have demonstrated that ID4 
expression is progressively lost with increasing stage of the prostate cancer disease 





LNCaP cells, low in PC3 cells and essentially absent in DU145 cells. Previous studies 
have also confirmed that lack of ID4 expression in DU145 cells is primarily due to 
promoter hyper-methylation.17, 19 Moreover, Chinaranagari et al., demonstrated that ID4 
is epigenetically silenced in prostate cancer due to promoter hyper-methylation through 
recruitment of EZH2, an histone acetyltransferase along with a corresponding increase in 
H3K27Me3.41    
       
Figure 7. Expression profile of ID4 correlates inversely with prostate cancer. (A) ID4 expression in 
prostate adenocarcinoma (PCa, blue) compared with adjacent normal prostate (ANP, pink) in TCGA 
prostate cancer adenocarcinoma (PRAD) gene expression (Illumina HiSeq) database. (B) In the MSKCC 
Prostate Adenocarcinoma dataset, 51.8% of those cases with altered ID4 expression demonstrated a 
significant reduction in disease-free survival rate compared with those in which ID4 expression was not 
altered. (C) Expression of ID4 is decreased in CRPC compared with that in hormone-naïve prostate cancer. 
 
2.11.4 ID4 and AR 
In the literature review, a few correlations between ID4, AR, and AR-dependent 
expression, suggests that there is a possible cross-talk between these two target proteins.2, 
17, 98 In case of prostate cancer, ID4 expression is progressively lost with increasing stage 





of ID4 expression are normally observed in the androgen-sensitive prostate cancer 
LNCaP cell line which has low tumorigenic potential. In contrast, ID4 is epigenetically 
silenced in the highly tumorigenic C81 cell line model, an androgen-independent 
derivative of LNCaP cells which are also found to be AR-positive.17, 19 In addition, Patel 
et al., demonstrated that knockdown of ID4 in LNCaP cells promotes metastatic and 
castration-resistant prostate cancer with a gene signature that resembles constitutive AR 
activity in castrated mice.2 Collectively, these findings implicate the potential role of ID4 
as a tumor suppressor, possibly by regulating AR activity in the prostate. The data 
obtained from the present study, along with continued research in this field, will assist in 
the development of new therapeutic strategies through which ID4 is primarily involved in 
the selective regulation of AR activity. This approach may be considered for therapeutic 
targeting, not simply in the context of cancer initiation and progression, but also in terms 






MATERIALS AND METHODS 
3.1 Prostate Cancer Cell Lines 
Human prostate cancer cell lines LNCaP, DU145 and PC3 were obtained from 
American Type Culture Collection (ATCC, Rockville, MD) and cultured as per ATCC 
recommendations as described previously.17 PC3 and DU145 cells were cultured in 
Ham’s F12 (Gibco, Carlsbad, CA) medium containing 10% bovine calf serum (Hyclone, 
Logan, UT) with appropriate antibiotics (pen/strep, fungizone, and gentamycin). LNCaP 
cells were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS) and 
appropriate antibiotics. Cells were cultured at 37°C in a fully humidified atmosphere 
containing 5% CO2. 
 
3.2 ID4 Silencing in Prostate Cancer Cell Lines 
The prostate cancer cell line LNCaP was used to stably silence ID4 using gene-
specific short hairpin RNA retroviral vectors (Open Biosystems #RHS1764 -97196818, -
97186620 and 9193923 in pSM2c, termed as ID4shRNA A, B and C respectively). 
LNCaP cells transfected with non-silencing shRNA (RHS1707) (L+ns) was used as a 
control cell line. Transfections and selection of transfectants (puromycin) were performed 
as suggested by the supplier. Successful silencing of ID4 gene was confirmed via qRT-





3.3 RNA Extraction 
Total RNA from L+ns and L(-)ID4 cells were isolated by an E.Z.N.A. DNA/RNA 
kit (Omega Bio-tek). The final RNA pellet was re-suspended in diethyl pyrocarbonate 
(DEPC)-treated H2O, quantified as per the manufacturer’s instructions and then stored at 
-80°C until further analysis.  
 
 3.4 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA (2 µg) isolated from cells was reverse transcribed to a final volume of 25µl 
as per the standard protocol,15, 98 (RT Master Mix: 1.25 mM each of dNTP’s, 250 ng 
oligo DT (Promega, Madison, WI), 10 mM dithiothreitol, and 200U MMLV reverse 
transcriptase (In-vitro) in the MMLV first-strand synthesis buffer (Invitrogen). RNA 
previously suspended in DEPC water was first denatured for 10 minutes at 65ºC, and then 
cooled on ice for 2 minutes before addition of reverse transcriptase master mix. The 
reverse transcriptase reaction was carried out in a thermocycler at 42ºC for 1 hour and 
95ºC for 5 minutes. The reverse transcribed RNA was stored at -20ºC until further 
analysis. 
 
3.5 Quantitative Real Time PCR (qRT-PCR) 
The reverse transcribed RNA from cell lines was used to perform RT-PCR and/or 
real-time qRT-PCR analysis using gene-specific primers (Table 2). The ΔCt values 
(respective gene value - Ct value subtracted from GAPDH Ct) and ΔΔCt values (fold 
change as compared to the gene expression levels in L+ns samples) was used as a 






Table 2. Primer Sequences for RT-PCR, Real-time qRT-PCR, and ChIP Analysis 
 
3.6 Protein Extraction 
Total cellular proteins were prepared from the cultured prostate cancer cell lines 
using M-PER (Thermo Scientific). Protein samples were quantitated using the BCA 
Protein Assay Kit according to manufacturer’s protocol (Thermo Scientific). A standard 
curve was determined using BSA and the absorbance values of the unknown protein 
samples were determined at a wavelength of 562 nm. Respective protein samples (20 
PCR primers Forward (5' ) Reverse (5') 
AR GAAGCCATTGAGCCAGGTGT TCGTCCACGTGTAAGTTGCG 
ARD1 GGAGAGCAAAGGCAATTCA CCTCTGAGCTGTCCTTGACA 
FKBP51 TTCCCTCGAATGCAACTCTC TCTACTGTTGCTCCTTCGTTTG 
FKBP52 AGCCCCAAACAGGACGAA AGTGTAGTGGACAAAGACTCGG 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC                
Hsp27                                       TCCCTGGATGTCAACCACTTCG                   GGGACAGGGAGGAGGAAACTTG 
PSA                                          GCTGTGAAGGTCATGGACCT                   CCAGCACACAGCATGAACTT 
CHiP Primers   
ETV1 TTTTGTGAATGGGACTGTCG AGGGGAACAAGATGGCTTTT    
FKBP51 GGAGCCTCTTTCTCAGTTTTG CAATCGGAGTGTAACCACATC 
PSA CATGTTCACATTAGTACACCTTGCC TCTCAGATCCAGGCTTGCTTACTGTC 





μg/μl) were then mixed 1:1 with 2X laemmli sample buffer for subsequent western 
blotting analysis. 
 
3.7 Western Blot Analysis  
20 μg of total proteins were size fractionated on 4-20% SDS-polyacrylamide gel. 
The SDS-gel was subsequently blotted onto a nitrocellulose membrane (Whatman) and 
subjected to western blot analysis using protein specific antibodies (Table 3). After 
washing with 1x PBS, 0.5% Tween 20, the membranes were incubated with horseradish 
peroxidase (HRP) coupled secondary antibody against rabbit/mouse IgG and visualized 
using the Super Signal West Dura Extended Duration Substrate (Thermo Scientific) on 
Fuji Film LAS-3000 Imager. 
 











ARD1 Santa Cruz 1:500 
FKBP51 Gift – Cox Lab 1:5000 
1:1000 




GAPDH Cell Signaling 1:1000 
Hsp27 Cell Signaling 1:1000 






3.8 AR Protein Stability Assay 
L+ns and L(-)ID4 cells were grown in RPMI 1640 medium containing 10% fetal 
bovine serum up to 75% confluency. Cells were treated with cycloheximide (100 µg/ml) 
for 0, 6, 12, 24, 30, and 36 hours, followed by preparation of whole cell lysates and 
protein extraction. AR protein levels were determined by western blot analysis with 
















            P-Hsp27 Enzo Life 
Sciences 
1:2000 
PSA DAKO 1:1000 
1:500 
TOPO I Santa Cruz 1:1000 
Pierce Goat Anti-Rabbit 
Poly-HRP  
Pierce Goat Anti-Mouse                                     
Poly-HRP 
 







ICC secondary antibodies      
DyLight 594 goat anti-
mouse (red) 
Thermoscientific 1:200 
DyLight 488 goat anti-
rabbit (green) 
Thermoscientific 1:200 
DyLight 594 goat anti-
rabit (red) 
Thermoscientific 1:200 







3.9 Chromatin Immunoprecipitation (ChIP) Assay 
Chromatin immunoprecipitation assay was performed using the ChIP assay kit 
(Millipore, Billerica, MD) as per the manufacturer’s instructions. Briefly, L+ns and L-
ID4 cells were grown in RPMI-1640 medium with 10% FBS (charcoal stripped) for 3 
days and treated with R1881 (10 nM) or vehicle for 24 hours. The chromatin (total DNA) 
extracted from cells was sheared (Covaris S220), subjected to immunoprecipitation with 
AR, mouse/ rabbit IgG and/or RNA polymerase II antibodies at 4°C overnight, reverse 
cross-linked and then subjected to real-time qRT-PCR analysis in the Eco Real-Time 
PCR system (Illumina). The previously published ChIP primer sets spanning the 
consensus androgen response element (ARE) sites in the promoters of PSA,194 
FKBP51,195 TMPRSS2, 196 and ETV1197 were used (Table 2). 
 
3.10 Luciferase Reporter Assay  
L+ns and L(-)ID4 cells were plated in a 96-well plate at a density of 2.5×104 
cells/well. After the cells attached, they were transiently transfected by mixing either 
mutated androgen response element (ARR3-luciferase) or AR response element driven 
luciferase reporter plasmid (PSA-luciferase) with pGL4.74 plasmid (hRluc/TK: Renilla 
luciferase, Promega) DNA in a 9:1 ratio with FuGENE HD transfection reagent 
(Promega) in a final volume of 100 µl of RPMI 1640 medium and incubated for 15 
minutes at room temperature. The transfection mix was then added to the cells followed 
by addition of R1881 (10 nM) or vehicle after 4 hours.  After a total of 24 hours, the cells 





reporter assay system (Promega) in LUMIstar OPTIMA (MHG Labtech). The results 
were normalized for the internal renilla luciferase control. Both of the luciferase plasmids 
were provided as a generous gift from Dr Amina Zoubeidi (University of British 
Columbia, Canada). 
 
3.11 Cell Proliferation Assay  
L+ns and L(-)ID4 cells were plated in a U-shaped 96-well plate at a density of 
5×103 cells/well. After the cells attached, they were treated with an increasing range of 
MJC13 drug concentrations (0 - 1000 µM) for 1 hour followed by the addition of R1881 
(1 nM) for 24 hours. Cell proliferation rates were then determined using CellTiter-96 
Non-Radioactive cell proliferation assay (Promega) as per the manufacturer’s 
instructions. 
 
3.12 Animal Studies  
 
3.12.1 Preparation of Tumor Cells  
L(-)ID4 cells were grown in complete medium (10% v/v FBS in RPMI-1640 
medium). When cells were 70-80% confluent, 3-4 hours before harvesting, medium was 
replaced with fresh medium to remove dead and detached cells. Then the medium was 
removed, and cells were washed with PBS. After adding appropriate amount of trypsin-
EDTA, cells were dispersed by adding complete medium (5:1), and then centrifuged 





medium (1:1), cells were counted using a Cellometer Vision Trio 5 system (Nexcelon 
Bioscience). 
 
3.12.2 Tumor Inoculation  
The work area was prepared by disinfecting all hood surfaces with 70% ethanol. 
The inoculation area of each mouse was cleaned and sterilized with an alcohol pad. A 
freshly prepared cell suspension was agitated to prevent the cells from settling, and then 
mixed with matrigel. One hundred microliter of the mixture (containing 2 × 106 L(-)ID4 
cells) was injected subcutaneously into the lower flank of each of the 14 (4-weeks old) 
castrated C.B-17 SCID mice (Taconic Biosciences) using a 27-gauge syringe. The C.B-
17 SCID mice were maintained at the Mercer University Vivarium. All studies were 
approved by the Clark Atlanta and Mercer University Committee for the use and care of 
animals (IACUC). Tumor diameters were measured with digital calipers, and the tumor 
volume was calculated each week using the equation [V (Volume) = (L (length) x W 
(width) 2)/2]. At the end of the experiments, the mice were laid to rest by asphyxiation, 
the tumors were surgically removed, weighed and the volume was measured. Harvested 
tumors were fixed in 10% buffered formalin. The fixed tumors were paraffin-embedded, 
sectioned (5 μm), and either stained with haematoxylin and eosin (H&E) or used for IHC. 








3.12.3 MJC13 Drug Treatments  
MJC13 drug therapy was started 5 weeks after inoculation, when the tumors 
reached an average volume of about 300 mm3. Mice were randomized into two groups 
with 6 mice in each group. The test group was administered 5 mg/kg of MJC13 via intra-
tumoral administration in the optimal co-solvent formulation consisting of PEG 400 and 
Tween 80 (1:1, v/v) twice weekly for a total of five consecutive weeks. The control group 
was administered the equivalent amount of co-solvent vehicle without MJC13 following 
the same schedule. Tumor volumes were recorded prior to each treatment.  
 
3.13 Immunohistochemistry  
IHC protein localization studies in paraffin-embedded 5-μm tissue sections were 
performed using protein specific antibodies (Table 3). Briefly, the slides were de-
paraffinized in xylene and re-hydrated through standard protocols. Following antigen 
retrieval (autoclave in 0.01 M sodium citrate buffer pH 6.0 at 121°C /20 psi for 30 
minutes), the peroxidase activity was blocked in 3% H2O2 and nonspecific binding sites 
blocked in 10% goat serum. The blocked sections were incubated overnight at 4°C with 
protein specific primary antibodies followed by incubation with secondary antibody 
(Table 3) for 1 hour. The slides were stained with DAB for 2 minutes, counterstained 
with haematoxylin, mounted with immuno-mount (Thermo Scientific), examined, and 
photo-micrographs were taken using the Zeiss microscope with an AxioVision version 
4.5 imaging system. All the antibodies were mono-reactive, that is a single reactive band 





LNCaP, DU1545 and PC3. Non-specific binding of the secondary antibodies was 
evaluated using respective normal IgGs (data not shown). 
 
3.14 ELISA Assays for Serum PSA Levels  
At the end of the animal studies, blood was drawn from all the MJC13 treated 
and/or untreated mice via cardiac bleed. After centrifuging to separate the serum fraction 
from the blood cells, the serum samples were analyzed for PSA levels using an enzyme-
linked immunosorbent assay. Briefly, the ELISA plates previously treated for the 
detection of human PSA by the manufacturer were used. 25 μl of MJC13 treated and/or 
untreated serum samples, and standards were added to each well with 100 μl of AB-
enzyme conjugate and incubated for 30 minutes at room temperature. The wells were 
washed with 300 μl of wash buffer followed by the addition of 100 μl TMB substrate per 
well and an incubation period of 15 minutes at room temperature. The reaction was 
stopped by adding 50 μl of stopping solution to all wells and absorbance was measured at 
450 nm using a Versa Max microplate spectrophotometer. 
 
3.15 Subcellular Fractionation  
L+ns and L(-)ID4 cells were serum-starved for 24 hours, prior to treatment with 
synthetic androgen (R1881, 10 nM) for additional 24 hours. Nuclear and cytoplasmic 
extracts were prepared from these cells using NE-PER protein extraction kit as per the 
manufacturer’s instructions (Thermo Scientific). Briefly, cells were lysed in a series of 
buffers and centrifugation steps to obtain a non-nuclear fraction and an intact nuclear 





were size fractionated on 4-20% SDS-polyacrylamide gel and then subjected to 
immunoblotting using protein specific antibodies (Table 3). The LAS 3000 imager (Fuji) 
and image quant software was used to capture and quantify the images.  
 
3.16 Immunocytochemistry  
L+ns and L(-)ID4 cells were grown on glass chamber slides up to 75% 
confluency in a 6-well plate. Twenty-four hours after plating, the complete medium with 
10% FBS was replaced with 10% charcoal-stripped media (csFBS). The slides were then 
washed with PBS (3x) and fixed in ice cold methanol for 10 minutes at room temperature 
and stored at 4°C until further use. Before use, the slides were equilibrated at room 
temperature, washed with PBS (5 minutes x 3), blocked with 1% BSA in PBST for 30 
minutes at room temperature and incubated overnight (4°C) with protein specific 
antibodies (1% BSA in PBST, Table 3). The slides were then washed in PBS and 
incubated with secondary antibody with fluorochrome conjugated to DyLight (Table 3) in 
1% BSA for 1 hour at room temperature in dark. The slides were subsequently washed 
again and stained in DAPI (1 µg/ml) for 1 minute and mounted with glycerol. Images 
were acquired by Zeiss fluorescence microscope through Axiovision software.  
 
3.17 Co-Immunoprecipitation (Co-IP) Analysis 
L+ns and L(-)ID4 cells were serum-starved for 24 hours, prior to treatment with 
R1881 (10 nM) for additional 24 hours Next, co-immunoprecipitation (Co-IP) analysis 
was performed using protein A coupled to magnetic beads (Protein A Mag beads, 





FKBP52 or –ID4) was first immobilized to Protein A Mag Beads by incubating overnight 
at 4°C.  To minimize the co-elution of IgG following immunoprecipitation, the 
immobilized IgG on protein A Mag beads was cross-linked in the presence of 20 mM 
dimethyl pimelimidate dihydrochloride (DMP) in 0.2 M triethanolamine, pH 8.2, washed 
twice in Tris buffer (50 mM Tris pH 7.5) and 1x PBS followed by final re-suspension and 
storage in 1x PBS. The cross-linked protein specific IgG-protein A-Mag beads were 
incubated overnight (4°C) with freshly extracted total cellular proteins (500 µg/ml).  The 
complex was then eluted with 0.1 M Glycine (pH 2-3) after appropriate washing with 1x 
PBS and neutralized by adding 10 μl of neutralization buffer (1 M Tris, pH 8.5) per 100 
µl of elution buffer. Eluted proteins were subjected to SDS-PAGE, transferred to 
nitrocellulose membrane, and then immunoblotted with protein specific antibodies (Table 
3). 
 
Table 4. Recombinant Proteins for Gluathione S-Transferase (GST) Pull-down and Poly-








Recombinant Proteins   Protein Tag 
His6-FKBP52    Poly-histidine Tag 
GST-AR   GST Tag 
GST-ID4   GST Tag 
GST-ID4 S73A   GST Tag 
GST-ID4 ∆A   GST Tag  





3.18 Poly-Histidine Pull-Down Assay 
Poly-histidine pull-down assays using wild-type His6-FKBP52, full-length ID4, 
and truncated ID4 constructs including ID4S73A (ID4 HLH mutant) and/or ID4∆A 
mutant (ID4 in which the alanine tract was deleted)198 were performed as per the 
manufacturer’s instructions (Pierce™ Pull-Down Poly Histidine Protein-Protein 
Interaction kit; Thermo Scientific, IL) (Table 4). Recombinant His6-FKBP52 plasmid 
was provided as a generous gift from Dr Marc Cox laboratory (University of Texas, El 
Paso, TX).     
 
3.19 GST-AR Pull-Down Assay 
Glutathione S-transferase (GST) Pull-Down assays using GST-Tagged AR, His6-
FKBP52, and recombinant ID4 proteins were performed as per the manufacturer’s 
instructions (Pierce™ Pull-Down GST Protein-Protein Interaction kit; Thermo Scientific, 
IL) (Table 4). Recombinant His6-FKBP52 and GST-tagged AR plasmids were provided 
as a generous gift from Dr Marc Cox (University of Texas, El Paso, TX) and Dr Amina 
Zoubeidi (University of British Columbia, Vancouver, Canada).    
 
3.20 GST-ID4 Pull-Down Assay   
Glutathione S-transferase (pReceiver-BO4) fused in frame to protein coding 
region of human ID4 (GST-ID4) plasmid was custom synthesized by Genecopoeia. Full-
length GST-ID4 and truncated GST-ID4 fusion proteins including ID4S73A (ID4 HLH 
mutant) and/or ID4∆A mutant (ID4 in which the alanine tract was deleted) were 





transformed into BL21 (DE3) competent cells (Novagen, Darmstadt, Germany). Protein 
expression in the freshly grown bacterial cultures at 370C was then induced by the 
addition of IPTG (1 mM) at 30°C. Four hours after induction, the BL21 (DE3) cells were 
centrifuged. The respective pellets were lysed at room temperature for 15 minutes in B-
PER (Thermoscientific, Inc) with DNase (3 units) and lysozyme (100 µg). The lysates 
were then centrifuged at 10,000 rpm for 10-15 minutes at 4°C. Next, the pellets were 
washed extensively with 1x PBS and boiled in SDS sample buffer. The GST-ID4 column 
bound proteins using LNCaP and DU145 whole cell lysates were size fractionated on 4-
20% SDS-polyacrylamide gel and then subjected to immunoblotting analysis using 
protein specific antibodies (Table 3). The LAS 3000 imager (Fuji) was used to capture 
the images. 
 
3.21 Statistical Analysis   
The National Institutes of Health (NIH)ImageJ,199 was used for counting cells 
stained positive for respective antigens in the IHC studies.98 Quantitative real-time (qRT-
PCR) data were analyzed using the ΔΔCt method.
19 The ChIP data was analyzed using % 
chromatin (1%) as input (Life Technologies). Data are expressed as mean ± SD from 
three different experiments. Within groups, statistical analyses were performed by 








4.1 ID4 Expression in Prostate Cancer Cell Lines    
Studies from our laboratory have previously shown that ID4 expression is high in 
androgen-responsive LNCaP cells, low in PC3 cells and essentially absent in DU145 
cells (Figure 8A). Lack of ID4 gene expression in DU145 cells was mainly attributed to 
promoter hyper-methylation at the epigenetic level.17 Moreover, ID4 gene expression 
levels were found to be significantly lower in the more tumorigenic LNCaP derived cell 
lines including C33 and C81 as compared to the less tumorigenic LNCaP cells.19 In 
general, LNCaP, LNCaP-C33, and LNCaP C-81 have been found to recapitulate many 
characteristics associated with progression of prostate cancer cells from androgen-
dependent to androgen-refractory phenotype.200 Consistent with the RT-PCR results, 
immunoblotting results also confirmed negligible ID4 protein levels in the androgen 
independent and highly tumorigenic DU145 cells as compared to the less tumorigenic 
LNCaP cells (Figure 8B). Overall, these results demonstrated that ID4 expression is 
progressively lost in the more aggressive androgen-independent prostate cancer cell lines 
including C81, DU145, and PC3.   
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Figure 8. Expression profile of ID4 in prostate cancer cell lines. (A) Reverse transcriptase polymerase 
chain reaction (RT-PCR) analysis of ID4 gene expression levels in DU145, DU145+ID4, C33, C81, and 
PC3 cell lines. (B) Western blot analysis of ID4 protein levels in DU145, DU145+ID4, LNCaP, and PC3 
cells lines. Actin was used as a loading control. 
 
4.2 Knockdown of ID4 Promotes Increased Tumor Growth of Subcutaneous 
Xenografts In Vivo 
Studies have previously shown that inactivation of ID4 in LNCaP cells promotes 
metastatic and castration-resistant prostate cancer with a gene expression signature that 
resembles constitutive AR activity.2 In these studies, L+ns and L(-)ID4 cells were 
subcutaneously injected into the flanks of non-castrated (NC) and castrated (C) nude 
male mice (Figure 9A)  to investigate the effect of ID4 knockdown on androgen-
dependent and –independent tumor formation respectively. L(-)ID4 tumors in NC mice 




were observed within 1 week of injection and grew progressively over the period of 6 
weeks by which time the experiment was terminated (Figure 9B). In contrast, a latent 
period of approximately 3 weeks of no L(-)ID4 tumor growth followed by accelerated 
tumor growth was observed in C mice (Figure 9B). In NC mice, the L+ns cells formed 
smaller tumors in 5 of 8 mice (62.5%), whereas no tumor was detected in 3 of 8 mice 
(37.5%) (Figure 9C). In contrast, the tumors were detected at the right flank of all 8 mice 
injected with L(-)ID4 cells (100%), suggesting that L(-)ID4 cells are capable of forming 
tumors even at castration levels of androgens (Figure 9C). The tumor weights and volume of 
L(-)ID4 cells were significantly higher than those of their control L+ns cells in both NC and C 
mice (Figure 9, D and E). In figure 9F, nearly three-fold higher levels of testosterone were 
observed in L(-)ID4 than in L+ns conditioned media. More importantly, the levels of 
testosterone in L(-)ID4 cells were similar to those observed in C81 cells, a cell line model 
that recapitulates the progression of human prostate tumor to the advanced hormone-
refractory stage.201-202 Collectively, these results indicated that knockdown of ID4 
enhances tumorigenicity of prostate cancer cells and promotes the CRPC phenotype.2 
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Figure 9. Inactivation of ID4 in LNCaP cells promotes tumor growth in vivo. (A) L+ns and L(-)ID4 cells 
in matrigel were injected into the left and right flanks of  nude mice (male nu/nu), respectively, as shown in 
the schematic diagram. Tumor growth is shown by solid circles. (B) Volume of the tumors were measured 
weekly (expressed as cubic millimeters, means ± SEM, n=6/group). The non-castrated mice were killed at 
6 weeks, whereas castrated mice were killed at 8 weeks. (C) Representative xenograft images with number 
of mice with similar tumor (n) are shown. (D and E) Respective volumes and weights (means ± SEM, n=6) 
of the tumors after excision from the mice (***, P<0.001, between L+ns and L(-)ID4 tumors in non-
castrated and castrated mice, respectively. (F) Testosterone ELISA analysis on L+ns, L(-)ID4, and C81 




conditioned media. Testosterone levels (Mean+SEM of three experiments in triplicate) are represented as 
ng/ml per 10,000 cells. C81 cells were used as positive controls.     
 
4.3 Expression Profile of ID4 and AR in Normal Prostate Epithelial (RWPE-1) and 
Prostate Cancer (LNCaP) Cells 
In normal prostate epithelial cells, ID4 have defined roles in regulating 
differentiated functions in response to androgens and local paracrine factors including 
HGF.203 However, the expression profile of ID4 in the context of androgen response in 
the normal prostate epithelial cell lines still remains largely unexplored. Therefore, we 
wanted to investigate, and also compare the expression profile of ID4 and AR in normal 
prostate epithelial cells (RWPE-1) versus androgen-responsive prostate cancer LNCaP 
cells. Interestingly, the expression profile of ID4, AR, and one of the major AR-regulated 
genes, PSA were found to be essentially absent in RWPE-1 as compared to the LNCaP 
cells (Figure 12A). In other words, RT-PCR results implicated that RWPE-1 might not be 
a desirable cell line model to investigate the normal physiological changes mediated by 
AR in the prostate epithelial cells as compared to its aberrant transcriptional activity in 
prostate cancer, represented by the androgen-responsive LNCaP cell line model. Our 
results also demonstrated that ID4 is present in AR positive LNCaP cells and more 
importantly, ID4 expression appears to be regulated by androgens, both at the gene and 
protein levels (Figure 12 B and C). Furthermore, knockdown of ID4 in LNCaP cells 
resulted in increased AR protein levels, implicating a possible cross-talk between ID4 
and AR (Figure 12D). Thus, due to the lack of a prostate epithelial cell line model that 
has endogenous expression of ID4, AR, and PSA, we focused our attention on the 




mechanistic insights of the ID4-mediated tumor suppressive effects in the selective 
regulation of AR activity in LNCaP cells compared to those of the ID4 knockdown 
LNCaP (L(-)ID4) cells. 
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Figure 10. Expression profile of ID4 and AR in RWPE-1 and LNCaP cells. (A) Reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis of ID4, AR, and PSA gene expression levels in RWPE-1 and 
LNCaP cells. (B and C) Gene and protein expression levels of ID4 were assessed via RT-PCR and western 
blot analysis. Cells were treated for 24 hours in the absence or presence of R1881 (10 nM) in the 10% 
charcoal-stripped fetal bovine serum. (D) Immunoblot analysis of AR protein levels in L+ns and L(-)ID4 
cells. Cells were treated for 24 hours in the absence or presence of R1881 (10 nM) and/or Casodex (30 
μM), lysed and lysates were electrophoresed and immunoblotted against AR antibody. 
 
4.4 AR Expression and Activity in ID4 Knockdown LNCaP Cells 
The androgen receptor (AR) is a nuclear receptor transcription factor required for 
normal prostate development and prostate cancer pathogenesis.204 The primary role of 
AR in prostate cancer is to regulate expression of the genes that are essential for prostate 




tumorigenesis.117 In Figure 11A, qRT-PCR results demonstrated an androgen-dependent 
increase in AR mRNA levels in L(-)ID4 compared with that in L+ns cells. Studies from 
our laboratory have previously shown that loss of ID4 promotes increased AR 
expression, and nuclear localization.2 Given that AR protein stability has been found to 
be increasingly associated with CRPC, we examined the effect of ID4 knockdown on AR 
protein turnover rates with the help of cycloheximide chase assay. Also, the main purpose 
of performing cycloheximide chase assay was to compare the stability profile of AR 
between L+ns and L(-)ID4 cells treated with cycloheximide, which is an inhibitor of 
protein biosynthesis due to its prevention in translational elongation. As shown in Figure 
11, B and C, cycloheximide treatment delayed AR protein degradation rate at different 
time points in L(-)ID4 cells compared with those in L+ns cells. These data suggest that 
loss of ID4 leads to an increase in the stability of AR protein. 
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Figure 11. Effect of ID4 knockdown on AR mRNA and stability of AR protein levels. (A) Comparison of 
AR mRNA levels in L+ns and L(-)ID4 cells as determined by real-time qRT-PCR analysis using AR-
specific primers. Cells were treated for 24 hours in the absence or presence of R1881 (10 nM) in 10% 
csFBS. Data were normalized to GAPDH followed by relative expression compared with the AR gene in 
L+ns (set to 1) (mean+SEM, n=3, *: P<0.001). (B) Immunoblot analysis of AR protein levels in response 
to cycloheximide treatment. L+ns and L(-)ID4 cells were grown in 10% fetal bovine serum (FBS) and 
treated with cycloheximide (100 µg/ml) for the indicated time points (0, 6, 12, 24, 30 and 36 hours). AR 
protein levels were determined by western blot analysis with primary antibody directed against AR. (C) 
Semi-quantitative AR protein levels normalized to GAPDH (loading control) and then to the individual AR 
protein levels in L+ns and L(-)ID4 from three different experiments as mean+SEM (*P<0.001). 
 
 
Given that loss of ID4 in LNCaP cells phenocopies AR activation,2 next we 
investigated the effect of ID4 knockdown on the expression levels of major AR-regulated 
target genes. In L+ns and L(-)ID4 cells, the gene and protein expression levels of AR-
regulated genes including PSA,205-206 FKBP51,207 and ARD1117 were assessed via RT-
PCR, qRT-PCR, and immunoblotting analysis. As anticipated, upon R1881 treatment, 
AR-dependent expression of PSA, FKBP51, and ARD1 were found to be significantly 
increased bin L(-)ID4 cells compared with those in L+ns cells, both at the transcript 
(Figure 12, A, B, C, and D) and protein levels,  implicating hormone-dependent activity 




of androgen receptor (Figure 12, E, and F). In addition, the protein levels of AR-
dependent expression including PSA, FKBP51, and ARD1 in L+ns and L(-)ID4 cells 
were significantly reversed by the antiandrogen Casodex, further confirming androgen-
AR dependent regulation. Interestingly, clinical dataset results obtained from The Cancer 
Genome Atlas (TCGA) prostate cancer adenocarcinoma (PRAD) gene expression 
(Ilumina HiSeq) database demonstrated increased AR-dependent expression including 
PSA, FKBP51, and ARD1, along with a significant decrease in ID4 expression levels in 
prostate adenocarcinoma as compared to the adjacent normal prostate (Figure 12). This 
database results suggests an inverse correlation between ID4 and AR-dependent 
expression with prostate cancer, further implicating a possible cross-talk between ID4 
and AR.    
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Figure 12. Effect of ID4 knockdown on gene and protein expression levels of major AR-dependent 
expression. (A-D) Comparison of AR-dependent expression including PSA, FKBP51, and ARD1 mRNA 
levels in L+ns and L(-)ID4 cells as determined by RT-PCR and qRT-PCR analysis using gene-specific 
primers. Cells were treated for 24 hours in the absence or presence of R1881 (10 nM) in 10% csFBS. Data 
were normalized to GAPDH followed by relative expression compared with the respective genes in L+ns 
(set to 1) (mean+SEM, n=3, *: P<0.001). (E) Immunoblot analysis of AR-dependent expression including 
PSA, FKBP51, and ARD1 in L+ns and L(-)ID4 cells. Cells were cultured for 24 hours in 10% csFBS 
before treatment with R1881 (10 nM) and/or R1881 (10 nM) ± Casodex (30 µM, antiandrogen) for another 
24 hours, lysed, and lysates were electrophoresed and immunoblotted for the indicated proteins. GAPDH 
was used as a loading control. A representative immunoblot of three different experiments is shown. (F) 
Semi-quantitative PSA, FKBP51, and ARD1 protein levels normalized to GAPDH and then to the 
individual protein levels in L+ns and L(-)ID4 from three different experiments as mean+SEM (*P<0.001). 
(G) ID4, AR, and AR-dependent gene expression including PSA, FKBP51, and ARD1 in prostate 
adenocarcinoma (PCa, blue) as compared to adjacent normal prostate (ANP, Pink) in The Cancer Genome 
Atlas (TCGA) prostate cancer adenocarcinoma (PRAD) gene expression (Illumina Hiseq) database. 
 
 
In the previous findings (Figure 12), a consistent increase in the expression levels 
of the major AR-regulated genes in L(-)ID4 cells implicated an increase in AR 
transcriptional activity. In order to further confirm that expression of these target genes is 
AR dependent, chromatin immunoprecipitation (ChIP) assay was performed between 
L+ns and L(-)ID4 cells, in the absence or presence of R1881 for 24 hours. Real-time 
quantitative PCR (qRT-PCR) analysis on chromatin immunoprecipitated (ChIP) DNA 
with AR antibody demonstrated a significant increase in the binding of AR to its 
respective androgen response elements on PSA, FKBP51, TMPRSS2 and ETV1 
promoters in L(-)ID4 cells compared with those in L+ns cells (Figure 13, A, B, C, and 
D). Furthermore, in a functional transcriptional assay using a AR response element (PSA-
luciferase) reporter plasmid, the relative PSA luciferase activity was found to be 
significantly higher in L(-)ID4 compared with those in L+ns cells, both in the absence or 
presence of R1881 (Figure 13, E, and F). The mutated AR luciferase reporter plasmid 
(ARR3-luciferase) used as a negative control, as expected did not result in luciferase 




activity in both these cell lines. Together, these results confirmed that knockdown of ID4 
in LNCaP cells stabilizes AR protein levels and potentiates AR-dependent expression and 
activity; further implicating that ID4 functions as a selective regulator of AR activity.  
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Figure 13. Effect of ID4 knockdown on AR-mediated transactivation. (A-D) Chromatin 
immunoprecipitation (ChIP) assay demonstrating the enrichment of AR (A, B, C and D) on the PSA, 
FKBP51, TMPRSS2, and ETV1 promoters. Androgen-starved L+ns and L(-)ID4 cells were treated with 
R1881 (10 nM) for 24 hours. Cells were fixed, chromatin sheared and precleared. ChIP assay was then 
performed with specific antibodies. The data expressed as percent input is mean+SEM of three experiments 
in triplicate between L+ns and L(-)ID4 cells (*: P<0.001). (E and F) The AR transcriptional activity was 
determined by transiently transfecting L+ns and L(-)ID4 cells with the AR response element driven 
luciferase reporter plasmid (PSA-luciferase), followed by treatment with R1881 (10 nM) or vehicle for 24 
hours. The data is normalized to Renilla luciferase. The luciferase reporter plasmid (ARR3-luciferase) was 
used as a negative control. The AR-luciferase reporter activity in L(-)ID4 was normalized to L+ns cells. 
The data from 3 different experiments in triplicate is expressed as mean+SEM (*: P<0.001). 
 
4.5 Molecular Mechanism through which Loss of ID4 Promotes CRPC 
As previously described (Figure 9), xenograft studies suggests that ID4 acts as a 
tumor suppressor in PCa and its loss, frequently observed in PCa promotes CRPC 
through constitutive AR activation. However, the main rationale behind the gain of 
CRPC phenotype of L(-)ID4 cells, both in vitro and in vivo, is poorly understood. In 
order to address the main etiology of ID4-mediated regulation of AR expression and 
activity, three important preliminary findings were generated in the lab. First, the RNA 
sequencing studies were performed to compare the gene expression profiles of 




significantly up-regulated and down-regulated genes in L(-)ID4 cells compared with that 
in L+ns cells. Second, quantitative proteomic analysis was performed to analyze 
differential protein expression profile between L+ns and L(-)ID4 cells. Among the most 
notable ones, there were 7 proteins up-regulated and 4 proteins down-regulated in L(-
)ID4 relative to L+ns cell lines (Figure 14A). These studies revealed distinct protein 
signatures in L(-)ID4 cells including important AR associated co-chaperones such as 
Hsp27 and FKBP52, the two well-characterized nuclear transporter208 and transcriptional 
activator3-6, 113-114 of androgen receptor (Figure 14A). Also, a two-step co-
immunoprecipitation followed by mass spectrometry analysis was performed in order to 
identify potential ID4 protein binding partners in prostate cancer L+ns cells, wherein ID4 
is endogenously expressed as shown in Figure 8. The probing of ID4 binding partners via 
co-immunoprecipitation and quantitative mass spectrometry analysis identified a total of 
22 different proteins. Interestingly, ID4 was found to interact with a wide variety of 
molecular chaperones and co-chaperones including FKBP52, Hsp90, Hsp10, Hsp70-2 
and many others (Figure 14B). RNA-sequencing studies revealed a gene expression 
profile consistent with activation of androgens in L(-)ID4 cells. There were about 18 







































Figure 14. Molecular basis of the CRPC phenotype in the L(-)ID4 cell line model. (A) Proteomic profiling 
of significantly up-regulated and down-regulated proteins in L(-)ID4 relative to L+ns cell lines. (B) ID4 
binding protein partners identified from prostate cancer LNCaP cells using a two-step co-
immunoprecipitation and mass spectrometry approach. 
 
4.6 Knockdown of ID4 Promotes Androgen Receptor-Mediated Transcriptional 
Activation through Hsp27 and FKBP52 
As mentioned earlier, while investigating the underlying molecular mechanism 
through which loss of ID4 potentiates AR transcriptional activity, quantitative proteomic 
results (Figure 14A) identified a 6.8 fold increase in heat shock protein 27 (Hsp27) 
protein levels, whereas a 3.4 fold increase in FK506-binding protein 4 (FKBP52) protein 
levels following the loss of ID4 in LNCaP cells (L(-)ID4). These two target proteins are 
well-established molecular co-chaperones,3-6, 208-209 known to be involved in potentiating 
aberrant AR activity during prostate cancer progression and development. Moreover, RT-
PCR, qRT-PCR and immunoblotting results confirmed significant up-regulation of 
Hsp27 and FKBP52 expression in L(-)ID4 cells compared with those in L+ns cells, both 
at the transcript (Figure 15, A, B, and C) and protein levels (Figure 15, D and E), further 
supporting the quantitative proteomic results (Figure 14A). Interestingly, Hsp27 
phosphorylation levels on Ser82 residue were found to be significantly elevated in the ID4 
knockdown LNCaP cells (Figure 15, D and E). Previous studies have shown that 
androgen-induced phospho-activation of Hsp27 on Ser78 and Ser82 residues displaces 
Hsp90 from a complex with AR to chaperone AR into the nucleus.208 Consistent with 
previous studies, ICC results demonstrated increased nuclear localization and co-
localization between AR and P-Hsp27 protein complexes in L(-)ID4 compared with those 
in L+ns cells (Figure 16).  
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Figure 15. Effect of ID4 knockdown on gene and protein expression levels of important AR co-
chaperones. (A, B, and C) Comparison of Hsp27 and FKBP52 (AR co-chaperones) mRNA levels in L+ns 
and L(-)ID4 cells as determined by RT-PCR and qRT-PCR analysis using gene-specific primers. Cells 
were treated for 24 hours in the absence or presence of R1881 (10 nM) in 10% csFBS. Data were 
normalized to GAPDH followed by relative expression compared with the respective genes in L+ns (set to 
1) (mean+SEM, n=3, *: P<0.001). (D) Protein levels of AR co-chaperones such as Hsp27, P-Hsp27 
[Ser82], and FKBP52 in L+ns and L(-)ID4 cells. Cells were cultured for 24 hours in 10% csFBS before 
treatment with R1881 (10nM) for another 24 hours, lysed, and lysates were electrophoresed and 
immunoblotted for the indicated proteins. GAPDH was used as a loading control. A representative 
immunoblot of three different experiments is shown. (E) Semi-quantitative protein levels normalized to 































Figure 16. Effect of ID4 knockdown on AR and P-Hsp27 nuclear localization and co-localization. 
Immunofluorescence co-localization of AR (red) and P-Hsp27 (green) protein complexes were assessed in 
L+ns and L(-)ID4 cells treated with R1881 (10 nM) for 24 hours in the 10 % charcoal-stripped fetal bovine 
serum. Red and green staining is gene specific and blue is 4’, 6-diamidino-2-phenylindole (DAPI) (see 
respective insets). A representative image of 3 experiments is shown. 
 
In the recent years, FKBP52 has emerged as an important co-activator of AR-
mediated transcription.3-6 Collective observations, prompted us to further investigate 




whether knockdown of ID4 promotes AR activation through FKBP52. Therefore, next 
we decided to block the FKBP52-regulated AR activity using a specific inhibitory 
compound known as MJC13.4, 6-7 MJC13 is a novel FKBP52 targeting agent that can 
specifically inhibit FKBP52-mediated potentiation of AR signaling through the putative 
targeting of the AR BF3 surface.6-7 The effects of MJC13 drug treatment (inhibitor of 
FKBP52-regulated AR activity) on AR-dependent gene expression including PSA and 
TMPRSS2 were assessed in L+ns and L(-)ID4 cells. We also assessed the impact of 
MJC13 treatment on the protein levels of AR-dependent expression including PSA and 
FKBP51 in these cell lines. Real-time PCR results demonstrated that MJC13 treatment 
effectively abrogated endogenous PSA and TMPRSS2 gene expression in a dose-
dependent manner in L+ns and L(-)ID4 cells (Figure 17, A and B). Immunoblotting 
results also confirmed a dose-dependent reduction in the protein levels of PSA and 
FKBP51 upon MJC13 treatment in L+ns and L(-)ID4 cells (Figure 17, C and D). 
However, inhibitory effects of MJC13 had no impact on AR mRNA and protein levels in 
these cells (Figure 17, A, B, C, and D), further implicating that FKBP52 is primarily 
involved in modulating AR activity and not expression. A similar decrease in the relative 
PSA luciferase activity was observed between L+ns and L(-)ID4 cells after treatment 
with MJC13 (Figure 17, E and F). In addition, MJC13 also inhibited androgen-dependent 
cell proliferation in L+ns and L(-)ID4 cells at concentrations consistent with those 
observed to be effective in reporter assays (Figure 17, G and H). Overall, MJC13 
treatments were found to be more effective in L(-)ID4 cells compared with that of the 
L+ns cells. Collectively, these results indicated that with subsequent loss of ID4, Hsp27 




and FKBP52 promotes nuclear translocation and transcriptional activity of AR, followed 
by increased cell proliferation in prostate cancer L(-)ID4 cells.  
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Figure 17. Effect of MJC13 drug treatment on AR activity and androgen-dependent cell proliferation rate. 
(A) AR, PSA, and TMPRSS2 gene expression levels in L+ns and L(-)ID4 cells were assessed by qRT-PCR 
analysis. Cells were treated for 24 hours with increasing concentrations of MJC13 as indicated above in the 
presence of 10% FBS. Data were normalized to GAPDH followed by relative expression compared with 
the respective genes in L+ns and L(-)ID4 (set to 1) (mean+SEM, n=3, *: P<0.001). (B) Immunoblot 
analysis of AR and AR-dependent expression including PSA and FKBP51 in L+ns and L(-)ID4 cells. Cells 
were treated for 24 hours with increasing concentrations of MJC13 as indicated above in the presence of 
10% FBS, lysed, and lysates were electrophoresed and immunoblotted for AR, PSA, FKBP51, and 
GAPDH (loading control). (C) The semi-quantitative protein levels were normalized to GAPDH and then 
to the individual protein levels in L+ns and L(-)ID4 from three different experiments as mean+SEM 
(*P<0.001). (D and E) The AR transcriptional activity was determined by transiently transfecting L+ns and 
L(-)ID4 cells with the AR response element driven luciferase reporter plasmid (PSA-luciferase), then 
treated with MJC13 (30 μM) for 1 hour followed by the addition of R1881 (1 nM) or vehicle for additional 
24 hours. The data is normalized to Renilla luciferase. The luciferase reporter plasmid (ARR3-luciferase) 
was used as a negative control. The AR-luciferase reporter activity in L+ns and L(-)ID4 cells treated with 
MJC13 were normalized to control L+ns and L(-)ID4 cells. The data from 3 different experiments in 




triplicate is expressed as mean+SEM (*: P<0.001). (F and G) Proliferation rate of L+ns and L(-)ID4 cells 
treated with a range of MJC13 drug concentrations as indicated above in the absence or presence of R1881 
(1 nM) for 24 hours was determined. Proliferation rate was expressed as absorption at 570 nm due to 
conversion of tetrazolium salt to formazan (mean+SEM, n=5, *: P<0.001).  
 
4.7 Inhibition of FKBP52-Regulated AR Activity Inhibits Tumor Growth of 
Subcutaneous Xenografts in Vivo 
To further validate the in vitro cell line data procured so far,  L(-)ID4 cells were 
subcutaneously injected into the flanks of four weeks old previously castrated male SCID 
mice to investigate the effect of  inhibiting FKBP52-AR signaling on the tumor growth of 
these subcutaneous xenografts in vivo via MJC13. First, a latent period of approximately 
two weeks of no L(-)ID4 tumor growth followed by accelerated tumor growth was 
observed in the castrated model of male SCID mice. Therapy was started 5 weeks after 
inoculation, when the tumors reached an average volume of about 300 mm3. Throughout 
the entire course of intra-tumoral drug treatments, the average tumor volume versus time 
for control (vehicle-treated) and test (MJC13-treated) groups were also determined for a 
total of 5 consecutive weeks. The data implicated that the MJC13 treatments started to 
inhibit the tumor growth from second week itself, but did not completely block the tumor 
growth (Figure 18A). At the end of the experiment (after 5 consecutive weeks of vehicle 
or MJC13 drug treatments), the tumors were excised and volume and weights were 
measured. In the treatment group, MJC13 drug treatments significantly attenuated the 
tumor growth of subcutaneous xenografts in vivo (75%) as compared to the control 
(vehicle-treated) tumors in the mice (Figure 18B). Also, the overall tumor weights 
(67.35%) and volumes (75%) were found to be significantly attenuated in the MJC13 
treated xenografts as compared to the control models of the castrated male SCID mice 




(Figure 18, C and D). Collectively, these results indicated that knockdown of ID4 
enhances tumorigenicity of prostate cancer cells in the CRPC conditions, more 
importantly through FKBP52-mediated AR signaling. 
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Figure 18. Inhibition of FKBP52-regulated AR activity via MJC13 drug treatments in L(-)ID4 xenografts 
Inhibits Tumor Growth In Vivo. (A) Volumes of the tumors were measured weekly (expressed as cubic 
millimeters, means ± SEM, n=6/group). Vehicle or MJC13 was administered via intra-tumoral injection 
twice weekly for a total of 5 consecutive weeks. The castrated male SCID mice were later sacrificed after 5 
consecutive weeks of vehicle or MJC13 drug treatments. (B) Representative xenograft images with number 
of mice with respective tumors (n) untreated/treated with MJC13 are shown. (C and D) Respective volumes 
and weights (mean + SEM, n=6) of the tumors after excision from the mice (***: P<0.001, between L(-
)ID4 tumors untreated/treated with MJC13).  
 
 




The histological examination of the tumors demonstrated an abundance of 
infiltrating red blood cells in the control as compared to the MJC13 treated L(-)ID4 
xenografts, suggesting increased vascularization (Figure 19B). We next investigated the 
immuno-histological localization of ID4, FKBP52, AR, AR-dependent expression 
including PSA, FKBP51, and also KI67, an important cell proliferation marker. These 
immuno-histological studies were performed in L(-)ID4 xenograft tumors extracted from 
castrated male SCID mice previously untreated and/or treated with MJC13. As expected, 
ID4 immunoreactivity was undetectable in L(-)ID4 xenografts (Figure 19B). IHC 
analysis of the xenograft tumors showed no change in AR and FKBP52 expression levels 
in both MJC13 treated and/or untreated xenograft tumors (Figure 19A). However, the 
AR-dependent expression including PSA and FKBP51 were found to be significantly 
attenuated in the MJC13 treated group than in control L(-)ID4 xenografts (Figure 19A). 
Moreover, MJC13 drug treatment also reduced the expression level of Ki67 as compared 
to the control xenografts (Figure 19B). Thus increased tumor growth in the control group 
resulted from an increase in proliferation of L(-)ID4 cells in vivo. Predominant human-
specific lamin A expression observed in both MJC13 treated and/or untreated L(-)ID4 
xenografts (Figure 19B) further suggested that increased tumor volume was due to the 
expansion of LNCaP cells and not due to mouse-derived stromal cells. Together, these 
results demonstrated that MJC13 drug treatment effectively abrogated AR-dependent 
expression and cell proliferation in L(-)ID4 xenografts, thereby further inhibiting tumor 
growth in vivo. In other words, increased tumor growth resulted from FKBP52-mediated 
AR signaling and increased cell proliferation of L(-)ID4 cells in vivo. 














                   
 
Figure 19. Histological and Immuno-histological Analysis of L(-)ID4 xenografts treated and/or untreated 
with MJC13. Immuno-histochemical localization (brown staining) of ID4, AR, PSA, FKBP51, FKBP52, 
KI67, and human-specific lamin A  in tumor xenografts. Hematoxylin and eosin staining of tumor 
xenografts. All images are representative and at 400x magnification. Representative data are shown. 
 
In order to recapitulate the previously shown IHC results (Figure 19), which 
demonstrated that MJC13 treatment significantly attenuated the expression levels of PSA, 
one of the major AR-regulated target genes, blood samples were collected from MJC13 
treated and/untreated xenograft models via cardiac bleed. Serum fraction was then 
isolated from the blood cells to measure the concentration of human PSA in the serum 
samples of these xenograft models previously untreated and/or treated with MJC13. As 
shown in figure 20, ELISA results demonstrated that MJC13 treatments significantly 
inhibited PSA secretion. Concomitant with the xenograft and IHC studies (Figure 18 and 
19), these results further confirmed that MJC13 treatments effectively abrogated 
FKBP52-mediated AR signaling in vivo. 
 





                                           
Figure 20. Serum PSA levels in MJC13 treated and/or untreated L(-)ID4 xenografts. At the end of the 
animal study, blood samples were collected from MJC13 treated and/or untreated xenograft models via 
cardiac bleed, serum fraction was isolated from the blood cells and then serum PSA levels (ng PSA per ml 
of serum) were determined by ELISA analysis. Data are presented as mean+SEM, n=6, ***: P<0.001, 
where n=6 animals in each of the MJC13 treated and untreated groups for the data shown in the panel. 
 
4.8 Increased Nuclear Localization and Co-Localization between AR and FKBP52 
Protein Complexes in ID4 Knockdown LNCaP cells 
Knockdown of ID4 in LNCaP cells significantly potentiated AR signaling through 
FKBP52 (Figure 17-20).  Given that nuclear localization of AR is an important 
prerequisite for its transcriptional activation, next we performed subcellular fractionation 
studies in L+ns and L(-)ID4 cells grown in the absence or presence of R1881 for 24 
hours, to investigate the effect of ID4 knockdown on AR and FKBP52 cellular 
localization. The immunoblotting analysis of cytoplasmic and nuclear extracts confirmed 
that a large fraction of AR and FKBP52 is nuclear in L(-)ID4 cells than in L+ns cells 
(Figure 21A). These results were also recapitulated in ICC studies, which confirmed that 
AR and FKBP52 is more nuclear in L(-)ID4 cells. Moreover, ICC results also 
demonstrated a significant increase in the nuclear localization and co-localization patterns 
Serum PSA Levels 




between AR and FKBP52 protein complexes in L(-)ID4 cells compared with those in 
L+ns cells upon R1881 treatment (Figure 21B).  
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Figure 21. Effect of ID4 knockdown on AR and FKBP52 nuclear localization and co-localization. (A) 
Cytoplasmic versus nuclear immuno-localization of AR and FKBP52 protein complexes were assessed in 
L+ns and L(-)ID4 cells treated with R1881 (10 nM) for 24 hours in the 10% charcoal-stripped fetal bovine 
serum. Topoisomerase (Topo1) and GAPDH was used to determine the purity and loading of nuclear and 
cytoplasmic extracts respectively. (B) Immunofluorescence co-localization of AR (red) and FKBP52 
(green) protein complexes were assessed in L+ns and L(-)ID4 cells treated with R1881 (10 nM) for 24 
hours in the 10 % charcoal-stripped fetal bovine serum. Red and green staining is gene specific and blue is 
4’, 6-diamidino-2-phenylindole (DAPI) (see respective insets). A representative image of 3 experiments is 
shown. 
 
4.9 Loss of ID4 Promotes AR Activity through Increased Protein-Protein 
Interactions between AR and FKBP52  
FKBP52 is an Hsp90-associated co-chaperone that has emerged as an attractive 
therapeutic target considering its functional specificity for a small subset of Hsp90 client 
proteins including androgen receptor.3 To test the effects of ID4 knockdown on AR-
FKBP52 complex formation and/or AR-Hsp90 complex dissociation, we performed co-
immunoprecipitation analysis of AR and FKBP52 in lysates of L+ns and L(-)ID4 cells 
grown in the absence or presence of R1881 for 24 hours. These studies provided a better 
mechanistic insight of the underlying molecular mechanism involved in the 
transcriptional activation of androgen receptor, following the loss of ID4 in LNCaP cells. 
Consistent with the previous findings (Figure 21B), in L(-)ID4 cells, western blot 
analysis of these co-immunoprecipiated samples demonstrated a significant increase in 
the protein-protein interaction between AR and FKBP52 protein complexes (Figure 22, A 
and B). In addition, ID4 knockdown both in the absence or presence of R1881, also led to 
complex dissociation between AR-Hsp90, further implicating that cytoplasmic AR 
rapidly translocated to the nucleus and interacts with sequence-specific androgen 
response elements to enhance its genomic activity.    
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Figure 22. Effect of ID4 knockdown on the protein-protein interactions between AR and FKBP52 protein 
complexes. The effects of loss of ID4 on AR-FBP52 interaction and/or AR-Hsp90 complex dissociation 
were assessed in L+ns and L(-)ID4 cells by co-immunoprecipitation and western blot analysis. Lysates 
prepared from cells grown in 10% charcoal-stripped fetal bovine serum (csFBS) in the absence or presence 
of R1881 (10 nM) for 24 hours were subjected to immunoprecipitation analysis with either an antibody 
directed against AR (A), and FKBP52 (B) and immunoblotted for the indicated proteins. 
 
4.10 ID4 Selectively Regulates AR Activity through Direct Interaction with FKBP52 
In Vitro 
In the present study, ID4 has been found to selectively regulate AR activity 
through FKBP52, both in vitro and in vivo. Furthermore, a two-step co-
immunoprecipitation and subsequent mass spectrometry analysis using ID4-specific 
antibody on the prostate cancer LNCaP cells enabled the identification of FKBP52 as a 
potential ID4 binding partner (Figure 14B). Among different ID4 protein binding 
partners summarized in Figure 14B, we focused on FKBP52 which also acts as an AR co-
regulator/co-chaperone. To confirm whether ID4 interacts with FKBP52 as part of a 
macromolecular complex involving AR, we performed an in vitro interaction assay using 
recombinant GST-AR, ID4, and FKBP52. These interaction studies in a way would not 
only help us to assess the ability of ID4 to interact directly with FKBP52 in vitro in the 




absence of other proteins, but also the ability of ID4 to influence FKBP52 interaction 
with AR. Thus, recombinant human ID4 was passed through a glutathione coupled 
sepharose column with bound GST-AR or without 6xHis tagged FKBP52 in a cell-free 
system. The bound proteins were eluted and detected on a western blot using ID4, 
FKBP52, and AR specific antibodies. As shown in Figure 23A, ID4 was detected in elute 
only when 6xHis-FKBP52 was passed through the column. These results suggested that 
ID4 does not directly bind to AR but indirectly through FKBP52 that in turn is shown to 
bind AR (Figure 23A). Direct interaction of ID4 to FKBP52 was next investigated using 
6xHis tagged FKBP52 bound to a nickel column followed by incubation with 
recombinant ID4. As shown in Figure 23B, a direct interaction between ID4 and FKBP52 
in the absence of other proteins was observed. Importantly, mutation of the highly 
conserved amino acid (S73A) located within the ID4 HLH domain completely disrupted 
the interaction between ID4 and FKBP52, whereas the mutation in the poly-alanine rich 
N-terminal tract of ID4 (∆A mutant) significantly abrogated this interaction (Figure 23B). 
These results were also recapitulated in GST-ID4 pull down studies using total LNCaP 
and DU-145 cell lysates, which confirmed that ID4 interacts with FKBP52 via its HLH 
domain (Figure 23C). Given that ID4 is undetectable or weakly expressed in prostate 
cancer DU145 cells (Figure 8), they provide an ID4-negative background as compared to 
the LNCaP cells wherein ID4 is endogenously expressed, further confirming the domain 
specific interaction between ID4, FKBP52, and AR protein complexes. These results led 
us to conclude that ID4 interacts with AR through FKBP52, which also supports the co-
immunoprecipitation and mass spectrometry data shown in figure 14B.    
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Figure 23. Interactions between ID4, AR, and FKBP52 protein complexes. (A) In vitro GST-pull down 
assays were performed with purified, recombinant GST-Tagged AR, His6-FKBP52, recombinant ID4 
alone, and different recombinant proteins together as shown. Proteins were visualized on westerns blots 
with primary antibodies specific to human AR, ID4, and FKBP52. (B) In-vitro Poly-histidine pull down 
assays were performed with purified, recombinant His6-Tagged FKBP52, recombinant full-length ID4, and 
truncated ID4 constructs including ID4S73A (ID4 HLH mutant) and ID4∆A mutant (ID4 in which the 
alanine tract was deleted) as indicated. Proteins were visualized on western blots with primary antibodies 
specific to human FKBP52 and ID4. (C) Pull down assays using LNCaP and DU-145 whole cell lysates 
were performed with recombinant full-length GST-ID4, or truncated GST-ID4 constructs including 
ID4S73A (ID4 HLH mutant) and ID4∆A mutant (ID4 in which the alanine tract was deleted), which were 
expressed in bacteria and purified using GST column and then subjected to western blot analysis using 
protein specific antibodies. 
 
4.11 ID4-FKBP52-AR Biological Network            
In summary, the data presented in the current study combined with those in our 
previous publications, an ID4-regulated AR signaling model through FKBP52 is depicted 
in Figure 24. In the androgen-responsive prostate cancer LNCaP cell line, we speculate 
that ID4 plays a pivotal role in selectively regulating AR transcriptional activity through 




direct and/or indirect interaction with FKBP52. Upon stable silencing of ID4 in LNCaP 
cells [L(-)ID4], elevated protein levels of AR associated co-chaperones including Hsp27 
and FKBP52, implicate their potential role in promoting constitutively active AR 
signaling. In other words, loss of ID4 promotes Hsp27 and FKBP52 dependent nuclear 
translocation and transcriptional activity of androgen receptor, leading to increased cell 
proliferation and progression of prostate tumorigenesis.  
              
Figure 24. Proposed mechanism of action of ID4. Predicted experimental model implicating the pivotal 







                                                           CHAPTER V 
                                               DISCUSSION 
5.1a Loss of ID4 Promotes CRPC Phenotype 
Emerging evidences implicate that epigenetic silencing of ID4 due to promoter 
hyper-methylation appears to be the key mechanism in many cancers including 
prostate.19, 41 In comparison to other ID proteins (ID1, ID2, and ID3) which acts as tumor 
promoters or supporting oncogenes,26-28 studies have confirmed that ID4 primarily acts as 
a tumor suppressor in most cancers including leukemia,29 colorectal,42-43 gastric,39 
prostate,17, 19-20, 41 and pancreatic cancers.40 Moreover, the Memorial Sloan Kettering 
Cancer Center (MSKCC) Prostate Adenocarcinoma dataset results suggested that ID4 
expression was down-regulated in 51.8% of clinical samples along with a significant 
reduction in the disease-free survival rates compared with that of cases expressing ID4.2 
ID4 expression was also found to be decreased in CRPC compared with that in hormone-
naïve prostate cancer in the prostate data set of Ta-mura et al210 in Oncomine.2 
Furthermore, in the present study, a strong association between ID4 and AR-dependent 
expression including PSA, FKBP51, and ARD1 in hormone-refractory metastatic 
prostate cancer shows direct clinical relevance of a possible cross-talk between ID4 and 
AR. The present study demonstrated that ID4 selectively regulates AR activity through 
direct interaction with FKBP52. Given that ID4 expression inversely correlates with 





attention on the LNCaP and stable LNCaP-ID4 cell lines, which mimics decreased ID4 
expression in PCa. 2, 18 In addition, these two cell lines closely resemble the androgen-
sensitivity of androgen receptor, in the absence or presence of ID4 and its subsequent 
transition to castration-resistant environment, both in vitro and in vivo.2, 201-202  
A recent study demonstrated that loss of ID4 attenuated normal prostate development and 
also promoted hyperplasia with subtle mPIN like lesions characterized by loss of 
NKX3.1 expression, an important androgen receptor regulated tumor suppressor gene.98, 
159 In addition, knockdown of ID4, which mirrors decreased ID4 expression in prostate 
cancer, resulted in increased tumorigenicity, both in vitro and in vivo. The important 
cancer phenotypes including proliferation, migration, invasion, and anchorage-
independent colony formation rates were also found to be relatively higher, following the 
loss of ID4 in LNCaP cells.2  
 
5.1b Knockdown of ID4 Leads to Increased Protein Stability and Transcriptional 
Activation of the Androgen Receptor 
AR remains important in the development and progression of prostate cancer and 
the majority of androgen-independent or hormone refractory prostate cancers express 
AR,73 which in part is associated with the extensive re-programming of its transcriptional 
activity.211 Oncogenic activation of AR during the development and progression of PCa, 
particularly in the early to late stages of CRPC is largely dependent on multiple factors 
including increased protein stability, post-translational modifications, interactions with 





lines of evidences confirming that ID4 plays a pivotal role in the selective regulation of 
AR expression and activity. First, there was a significant increase in the basal AR protein 
levels and AR protein stability in L(-)ID4 cells compared with those in L+ns cells. 
Second, qPCR and immunoblotting blotting results demonstrated a significant increase in 
the AR-dependent expression including PSA, FKBP51, and ARD1, both at the transcript 
and protein levels. Finally, chromatin immuno-precipitation (ChIP) and luciferase 
reporter assays results confirmed increased transcriptional activity of androgen receptor 
in the ID4 knockdown LNCaP cells. In addition, we also observed a significant increase 
in the sensitivity of androgen receptor response to R1881 treatments in L(-)ID4 cells. 
Together, following the knockdown of ID4 in LNCaP cells [L(-)ID4], increased protein 
stability along with the constitutive activation of androgen receptor marked by increased 
AR-dependent expression including PSA, FKBP51, and ARD1 as well as ability to 
interact with the promoter elements in the androgen-responsive genes such as PSA, 
FKBP51, TMPRSS2, and ETV1 unequivocally supports the tumor suppressor role of ID4 
in the regulation of AR expression and activity. 
 
5. 2 Knockdown of ID4 Potentiates AR Signaling through Increased Protein-protein 
Interactions with FKBP52 
Co-immunoprecipitation followed by quantitative mass spectrometry analysis 
identified different ID4 protein binding partners; most of these proteins and their 
biological significance have been well documented. Intriguingly, our list of ID4 putative 





wide gene family, whose components are involved in processes of protein folding, 
activation, trafficking, and transcriptional activity of most steroid receptors, including 
AR.208 For example, Hsp90 is an important molecular chaperone, and the relationship 
between the chaperoning functioning of Hsp90 with AR stability, conformation, and 
modulation of ligand binding is well characterized.212-213 Whereas, Hsp10 is a 10 kDa 
highly conserved, mitochondrion-resident protein, which co-chaperones with another 
mitochondrial heat shock protein Hsp60 for protein folding as well as the assembly and 
disassembly of important protein complexes.214 In addition to these ID4 protein partners, 
the current approach also identified FKBP52 as a potential ID4 binding partner in 
prostate cancer LNCaP cells. Furthermore, mutation of the conserved serine to alanine 
(ID4S73A HLH mutant) in the HLH domain of ID4 resulted in loss of its interaction with 
FKBP52, suggesting that the interaction with FKBP52 is dependent on the intact HLH 
domain of ID4. Interestingly, deletion of the alanine residues (39-48, ID4∆ mutant) in 
ID4 (specific only to ID4 and no other ID family members) did not result in complete 
abrogation of the binding but the interaction appeared to be significantly weaker as 
compared to wild type ID4. Collectively, these results suggest the functional significance 
of HLH domain and poly-alanine stretch of ID4 in ID4-FKBP52 interactions. In this 
study, we did not observe a direct interaction between ID4 and AR, further implicating 
that ID4 could possibly regulate AR activity indirectly through FKBP52. Furthermore, 
knockdown of ID4 in LNCaP cells resulted in increased nuclear localization and co-
localization of AR-FKBP52 protein complexes, following the androgen-induced AR-





Quantitative proteomic analysis identified distinct protein signatures in L(-)ID4 
cells including important AR co-chaperones such as Hsp27 and FKBP52, the two well-
characterized nuclear transporter208 and transcriptional activator3-6, 113-114 of androgen 
receptor. In recent years, Hsp27 and FKBP52 have been identified among the most 
consistently overexpressed genes in hormone-refractory prostate cancer xenografts.7, 209 
Increased cellular localization and co-localization between AR and P-Hsp27 protein 
complexes further highlights the pivotal role of Hsp27 in the nuclear transport of AR in 
L(-)ID4 cells. Furthermore, inhibiting FKBP52-regulated AR activity via the lead 
compound, termed MJC13, significantly abrogated AR-dependent expression, activity, 
and androgen-stimulated proliferation in L(-)ID4 cells. Collectively, these results 
demonstrate that with ID4 knockdown [L(-)ID4], Hsp27-dependent nuclear translocation 
and FKBP52-potentiated AR signaling, further leads to increased tumorigenicity, both in 
vitro and in vivo. 
The most notable observation made in the present study was that loss of ID4 
enhances in vivo tumor growth in the castration resistant environment, more importantly 
through FKBP52-mediated AR signaling pathway. Consequently, inhibiting FKBP52-
regulated AR activity through MJC13 drug treatment in L(-)ID4 xenografts significantly 
attenuated the tumor growth in vivo. Concomitant with xenograft studies, molecular 
techniques including ELISA and IHC analysis highlights the importance of AR signaling 
in the tumor growth in an androgen-depleted environment, further implicating the 
specificity of tumor-suppressive effects of ID4 in the selective regulation of AR activity 





publications, an ID4-regulated AR signaling model is depicted in figure 24. In this 
pathway, ID4 appears to selectively regulate AR activity through direct interaction with 
FKBP52 in vitro. Our data also suggest that in the absence of ID4, FKBP52 significantly 





                                                           CHAPTER VI 
                                                           CONCLUSION 
The androgen receptor signaling axis has now emerged as a major contributor to 
prostate cancer initiation, progression, and metastatic spread of prostate cancer.71, 215-216 
The underlying mechanisms involved in the regulation of AR signaling especially in the 
early to late stages of castration-resistant prostate cancer (CRPC) will remain to be the 
focus of intense investigation in current as well as the future research studies.87, 217-218 
Consistent with our previous studies,2 results from the current findings demonstrated that 
knockdown of ID4 in LNCaP cells promotes increased tumorigenicity with a gene 
expression signature that resembles constitutive AR activity. Our results, in general, 
agree with the majority of results that support the role of ID4 as a tumor suppressor 
primarily through selective regulation of AR activity by disrupting AR-FKBP52 
interaction in prostate cancer. Regardless of the manner in which ID4 and FKBP52 
interact to regulate AR activity, our data suggests a clear inhibitory relationship between 
these two target proteins. Furthermore, to validate the functional relationship between 
ID4 and FKBP52 in regulating AR signaling, in vitro pull-down studies using multiple 
domain-specific ID4 and FKBP52 constructs needs to be performed. Given the critical 
role of the FKBP52 proline-rich loop that overhangs the PPIase pocket in the regulation 
of AR activity,4 we speculate that ID4 could target distinct regulatory sites within  





presented in this study represents a strong possibility that restoring ID4 expression would 
not only serve as a valuable pharmacological tool for selectively regulating FKBP52-AR 
interaction, but it might also represent a promising therapeutic approach to inhibit 
aberrant AR activity in the castration-resistant environment. This approach may be 
considered for therapeutic targeting, not simply in the context of cancer initiation and 
progression, but also through its overall involvement in the regulation of tissue 
physiology.
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